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We are currently in the midst of the most aggressive and fulminating outbreak of Ebola-related disease, commonly
referred to as “Ebola”, ever recorded. In less than a year, the Ebola virus (EBOV, Zaire ebolavirus species) has infected
over 10,000 people, indiscriminately of gender or age, with a fatality rate of about 50%. Whereas at its onset this
Ebola outbreak was limited to three countries in West Africa (Guinea, where it was first reported in late March 2014,
Liberia, where it has been most rampant in its capital city, Monrovia and other metropolitan cities, and Sierra
Leone), cases were later reported in Nigeria, Mali and Senegal, as well as in Western Europe (i.e., Madrid, Spain) and
the US (i.e., Dallas, Texas; New York City) by late October 2014. World and US health agencies declared that the
current Ebola virus disease (EVD) outbreak has a strong likelihood of growing exponentially across the world before
an effective vaccine, treatment or cure can be developed, tested, validated and distributed widely. In the meantime,
the spread of the disease may rapidly evolve from an epidemics to a full-blown pandemic. The scientific and
healthcare communities actively research and define an emerging kaleidoscope of knowledge about critical
translational research parameters, including the virology of EBOV, the molecular biomarkers of the pathological
manifestations of EVD, putative central nervous system involvement in EVD, and the cellular immune surveillance to
EBOV, patient-centered anthropological and societal parameters of EVD, as well as translational effectiveness about
novel putative patient-targeted vaccine and pharmaceutical interventions, which hold strong promise, if not hope,
to curb this and future Ebola outbreaks. This work reviews and discusses the principal known facts about EBOV
and EVD, and certain among the most interesting ongoing or future avenues of research in the field, including
vaccination programs for the wild animal vectors of the virus and the disease from global translational science
perspective.
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On the 23rd of March 2014, the World Health
Organization (WHO) was notified of an outbreak of
Ebola virus disease (EVD), a type of aggressive he-
morrhagic fever with a high average fatality rate, which
had apparently begun three months earlier, in December
2013, in Méliandou a town of 12,000 people located in the
Préfecture de Guékédou, N’zerekore Region of the Guinée
Forestière, in the eastern sector of the Republic of Guinea,
on the Atlantic coast of West Africa. Soon, cases were
confirmed across Guinea, including in the Guinean* Correspondence: fchiappelli@dentistry.ucla.edu
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unless otherwise stated.capital, Conakry, as well as in neighboring Sierra Leone,
and in the Republic of Liberia, including its capital
Monrovia.
Previously known as Ebola hemorrhagic disease, EVD
had until now only manifested in a few focal tropical re-
gions of Sub-Saharan Africa. From 1976, when EVD was
first identified, through 2013, WHO had reported in
total fewer than 2,000 confirmed cases. But, as of early
August 2014, the number of cases of the present epi-
demic had already surpassed the number of confirmed
cases of the previous outbreaks combined. As of mid-
Fall 2014, the number of deaths attributed to EVD was
close to 5,000, including a fatality on US soil [1].
The efforts of WHO have been to contain and to pre-
vent further spreading of EVD, while supporting at-riskral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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virus (EBOV), the causative agent of EVD, is classified as a
Category-A infectious substance by the U.S. Department
of Transportation’s Hazardous Materials Regulations
(HMR:49 C.F.R., Parts 171–180) [1,2].
Professor Peter Piot, now director of the London
School of Hygiene and Tropical Medicine, and his team
first identified Ebola, on the 26th of August 1976, in
Yambuku, a small rural village in Mongala District
of northern Democratic Republic of the Congo (then
known as Zaire). The first victim, patient zero for EVD,
was the village school headmaster Mabalo Lokela, who
had toured an area near the Central African Republic
border along the Ebola river between the 12th and the
22nd of August of that year. The virus responsible
for Mr. Lokela’s initial infection was first thought to be
Marburg virus (MBGV), but later identified as a new
type of virus related to MGBV, and named after the
nearby Ebola river. Two weeks after the first onset of
symptoms, on the 8th of September, Mr. Lokela died of the
disease resulting from this infection with the Ebola virus.
The specific species of EBOV responsible for the first out-
break in the Democratic Republic of the Congo, now Zaire,
was called the Zaire EBOV ebolavirus species [1].
Subsequently a number of additional cases were re-
ported. Nearly all were centered in the Yambuku mis-
sion hospital, or were traced to individuals having had
close contact with its patient and health care provider
population. A total of 318 cases were diagnosed and
280 deaths were recorded, corresponding to an 88%
fatality rate. A second EBOV species, Sudan EBOV,
was identified that same year when EVD erupted in
Sudan, and claimed 284 infected people, and 151
deaths (53% fatality rate) [1]. This new emerging ful-
minating contagious viral disease stunned the World
health community.
These initial Ebola outbreaks were contained with the
help of WHO, the Congolese air force that secured
transport of necessary medical supplies, food and water,
and by common-sense public health protocols, including
quarantining villagers, sterilizing medical equipment,
and providing protective clothing (i.e., personal protec-
tive equipment, PPE) [1].
EVD reappeared in the Democratic Republic of Congo
two decades later, in 1995. With a fatality rate of 81%,
this Zaire EBOV species outbreak affected 315, killing
254 people. This prompted the Infectious Diseases jour-
nal, published by the CDC, to produce its first Ebola
article in its first volume (number 3).
Fifteen years later (2000), Uganda suffered a Sudan
EBOV species outbreak, which targeted 425 people, kill-
ing 224 (53% fatality rate). Three years later (2003), the
Zaire EBOV species struck Zaire again, infecting 143
people, with a 90% fatality rate (128 deaths).Yet again in 2007, the Zaire EBOV species struck in
the village of Kampungu of the Kasai-Occidental region
of the Democratic Republic of the Congo, about 420
miles from Kinshasa. The disease was contained only
after it had spread to four contiguous villages: in total,
264 individuals fell sick, with a fatality rate of 71% [1].
One key 2007 study [2] tested 54 specimens obtained
from 26 patients of this 2007 outbreak, 12 of who had
died of Ebola. The samples were collected, and stored in
liquid nitrogen until a batch-reverse transcription poly-
merase chain reaction (RT-PCR) assay was performed.
Sixteen clinical specimens from 12 patients were positive
by virus culture (25% true positives) and RT-PCR (100%
true positives). All samples of plasma and serum (16 of 16),
tears (1 of 1), nasal blood (1 of 1) and breast milk (2 of 2)
were positive for EBOV. Half of the samples of saliva (8 of
16) were positive by RT-PCR, as well as half of the stool
and semen samples. None of the samples of sputum, sweat
or vomit showed any trace of the virus by RT-PCR. The
shedding of EBOV in blood and saliva corresponded al-
most exactly to the period of acute viremia and associated
EVD symptomatology. Positive saliva specimens were ob-
tained not before day 8 after disease onset. No sample was
tested positive during the prodromic phase of the disease.
Based on those preliminary pilot data, inferences were
drawn that EBOV might not be contagious during the
asymptomatic phase of infection, and that EBOV is found
primarily in bodily fluid, and thus might be transmitted
only thusly. In retrospect, however, this study appears now
to have been grossly under-powered to warrant application
of these inferences in the present outbreak.
Later that same year, on the 30th of November 2007,
the Uganda Ministry of Health confirmed EVD in the
Bundibugyo District in Western Uganda. The virus
sample was tested and the findings, confirmed by the US
National Reference Laboratories, CDC, and WHO, re-
vealed the emergence of a third and new EBOV species,
which was named Bundibugyo. That outbreak claimed
149 victims, of whom 37 were lethal cases (25% fatality
rate) [1].
Five years later (2012), again in Uganda, the Sudan
EBOV species struck twice, but both outbreaks were im-
mediately contained with only seven people infected on
the first and 24 on the second, and a fatality rate of 57%
and 71% respectively. On the 17th of August 2012, the
Ministry of Health of the Democratic Republic of the
Congo reported Bundibugyo-EBOV disease in the eas-
tern region, about the towns of Isiro and Viadana. Of 57
people who fell sick, 29 perished (51% fatality rate) [1].
The current fulminating outbreak (Zaire EBOV species)
was first reported a year and a half later, on the 23rd of
March 2014 in Guinea, West Africa. Patient zero was
identified to be a two-year old child who had died on the
28th of December 2013. Professor Piot was quoted as
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May, in Guinea. Then a famous woman, a traditional
healer, died, and at her funeral hundreds of people
touched the body. Then there was this explosion in three
countries…” (The Telegraph, 19 October 2014). Since
then, the disease has spread rapidly to the neighboring
West African countries of Liberia and Sierra Leone. Con-
trary to the previous outbreaks that had been predomi-
nantly localized in the countryside and rural villages and
town, it soon invaded the capitals of Monrovia and
Conakry, as well as other regional metropolitan centers.
The present situation has been qualified as a
“catastrophic” epidemic “deteriorating daily” (Médecins
sans Frontières, [Doctors without Borders], statement
mid-August 2014) [1]. The October 2014 issue of the
CDC journal Emerging Infectious Diseases (vol 20, No 10)
provided a spotlight of our current over-arching know-
ledge on Ebola.
The current EVD trends are aggressive and fast
spreading beyond the infection’s original regional boun-
daries. These characteristics, taken together with the ex-
tensive traveling that globalization presently entails, raise
the specter of an emerging world-wide pandemic. WHO
declared the current EBOV epidemic to be an international
public health emergency on the 8th of August 2014.
On the 30th of September 2014, the first confirmed
case of Ebola was diagnosed in the United States. By
mid-September, cases had been confirmed in Nigeria, as
well as Madrid, and suspected in France, Ireland, and
Australia. Senegal, by aggressively shutting down its
borders, declared itself a country “free of Ebola”. In a
statement issued on the 26th of September of that same
year, WHO deplored that “…the Ebola epidemic ravaging
parts of West Africa is the most severe acute public
health emergency seen in modern times. Never before in
recorded history has a biosafety level four pathogen in-
fected so many people so quickly, over such a broad geo-
graphical area, for so long…”, and announced that the
number of diagnosed cases had surpassed 8,000, with a
close to 50% fatality rate. Of particular concern was the
fact that close to 250 healthcare workers were among
the dead, partly due to the lack of, or misuse of the PPE
equipment, and long exhaustive hours [1,2]. By the end
of the month of October 2014, WHO statistics indicated
over 13,703 known cases of Ebola worldwide, with 4,922
deaths (35.9% fatality rate).
With respect to PPE, the CDC recommended “…in-
cluding, at a minimum, disposable gloves, gown (fluid
resistant/impermeable), eye protection (goggles or face
shield), and facemask to protect against direct skin and
mucous membrane exposure of cleaning chemicals, con-
tamination, and splashes or spatters during environmental
cleaning and disinfection activities. Additional barriers
(e.g., leg covers, shoe covers) should be used as needed. Ifreusable heavy-duty gloves are used for cleaning and disin-
fecting, they should be disinfected and kept in the room or
anteroom. Be sure that are instructed in the proper use of
personal protective equipment including safe removal to
prevent contaminating themselves or others in the process,
and that contaminated equipment is disposed of appro-
priately….” [2].
The CDC also instructed “…(to) use a U.S. Environ-
mental Protection Agency-registered hospital disinfectant
with a label claim for a non- enveloped virus (e.g., noro-
virus, rotavirus, adenovirus, poliovirus) to disinfect envir-
onmental surfaces in rooms of patients with suspected or
confirmed Ebola virus infection. Although there are no
products with specific label claims against the Ebola
virus, enveloped viruses such as Ebola are susceptible to
a broad range of hospital disinfectants used to disinfect
hard, non-porous surfaces. In contrast, non-enveloped vi-
ruses are more resistant to disinfectants. As a precaution,
selection of a disinfectant product with a higher potency
than what is normally required for an enveloped virus is
being recommended at this time. EPA-registered hospital
disinfectants with label claims against non-enveloped vi-
ruses (e.g., norovirus, rotavirus, adenovirus, poliovirus)
are broadly antiviral and capable of inactivating both
enveloped and non-enveloped viruses…” [2]. The means
of disinfection that are reported of common use in West
Africa at the moment include copious drenching with
bleach.
It has now come to light that the majority of health care
workers worldwide do not have sufficient training in the
PPE and disinfection protocols that EBOV contamination
requires. Most hospitals in the US are reported not to
have in stock the appropriate materials to ensure the
safety of the nursing and medical staff. CDC and WHO
issued updates and revisions of their protocols in mid
October 2014. Taken together, this fluid situation contri-
butes to the state of heightened alert, concern and anxiety
among professionals and the general population. President
Obama appointed Ron Klain as “Ebola Response Coor-
dinator” to manage the national response efforts at diag-
nosis, quarantine, treatment and prevention of Ebola on
the 17th of October 2014.
By the 6th of October 2014, the first case contracted on
European soil was reported in Madrid, Spain: Teresa
Romero, a doctor who had been caring for two missionary
priests who had just died of Ebola in Madrid. This was the
first case of Ebola diagnosed outside of the African contin-
ent. On the 8th of October 2014, Thomas Eric Duncan
the first patient who developed Ebola on US soil, became
the first Ebola patient to die on US soil. He had assisted
a pregnant woman, apparently Ebola-negative (that is,
showing no fever or other EVD symptoms as per the re-
ports of her family and community healthcare personnel)
at the time. She had collapsed due to excessive pre-partum
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On the 20th of September, Mr. Duncan had returned to
the US. A few days later the woman gave birth to an ap-
parently healthy baby, albeit premature by a few weeks.
She continued to have extensive vaginal bleeding post-
delivery and later died; the infant, deprived of her natural
mother’s milk, was fed on artificial milk, but, whereas he
had shown signs of stabilizing following the eventful birth,
choked on the formula milk and died a few days later.
According to official Liberian reports, neither mother nor
infant had confirmed EVD; but, the popular press had
drawn the association of Mr. Duncan falling ill with Ebola
following his last good deed before coming to the US from
Liberia, which was a long-planned trip to visit his son and
his fiancée in Dallas. On the 24th of September, following
his arrival in the US, Mr. Duncan developed the first
symptoms of incipient fever. He sought hospitalization on
the 26th of September, but was immediately discharged
despite a temperature above 100°F, and having clearly
stated to the hospital staff his recent arrival from Liberia.
On the 28th of September, he returned to the hospital,
was diagnosed and placed in isolation, and passed away
from Ebola 10 days later. Mr. Duncan’s relatives and care-
givers were placed in quarantine, but none of them devel-
oped fever or any EVD symptoms. Two of the nurses who
cared for Mr. Duncan at the Texas hospital, Nina Pham
and Amber Vinston, were the first two secondary cases of
diagnosed Ebola outside Africa and on US soil. They both
were successfully cured from the disease.
Assuming no change in the control measures for the
present epidemic, the cumulative reported numbers pre-
dict an exponential growth of the epidemic, along with
atrociously high numbers of Ebola-infected and Ebola fa-
talities by early 2015. In this, as in the previous Ebola
outbreaks, the majority of Ebola patients are young
adults 15 to 44 years of age (49.9% male), with an asymp-
tomatic period of 1–21 days (median = 11.4 days; serial
interval = 15.3 days). On the basis of the initial periods of
exponential growth, the estimated basic reproduction
numbers (R0) have been reported to be 1.71 (confidence
interval, CI95: 1.44 to 2.01) for Guinea, 1.83 (CI95: 1.72 to
1.94) for Liberia, and 2.02 (CI95: 1.79 to 2.26) for Sierra
Leone, the three fulcrum countries of this present out-
break. The estimated current reproduction numbers (R)
are 1.81 (CI95: 1.60 to 2.03) for Guinea, 1.51 (CI95: 1.41 to
1.60) for Liberia, and 1.38 (CI95: 1.27 to 1.51) for Sierra
Leone. Therefore, the corresponding doubling times were
derived to be 15.7 days (CI95: 12.9 to 20.3) for Guinea,
23.6 days (CI95: 20.2 to 28.2) for Liberia, and 30.2 days
(CI95: 23.6 to 42.3) for Sierra Leone [3]. These data suggest
that different mutations of the Zaire species may cha-
racterize each of the three fulcrum countries. If molecular
analyses should confirm this hypothesis, the difficulty
and complexity to raise an effective vaccine wouldconsiderably increase. As things stand, CDC reports that,
at the very best, an effective vaccine against EBOV could




The Ebola River flows through the hills and the planes
of northern Zaire, now the Democratic Republic of the
Congo. Ebola is the headstream of the Mongala River, a
tributary of the Congo River. Along these banks, the
Ebola virus was first discovered in the mid seventies. In
1998, the genus of that virus family was first introduced
as the “Ebola-like viruses” (Vertebrate Virus Subcommittee
proposal to the International Committee on Taxonomy of
Viruses [ICTV]). By 2002 the international community
came together to simplify the nomenclature, and changed
its name to Ebola virus (EBOV, ebolavirus).
The genus ebolavirus, closely related to the Marburg
virus, belongs to the negative strand RNA family of
Filoviridae, order Mononegavirales. Negative-sense viral
RNA is complementary to mRNA and thus must be
converted to positive-sense RNA by an RNA polymerase
before translation. As such, purified RNA of a negative-
sense virus is not infectious by itself as it needs to be
transcribed into positive-sense RNA, although each
virion can be transcribed to several positive-sense infec-
tious RNAs. RNA viruses in general, and negative sense
RNA viruses in particular have high mutation rates com-
pared to DNA viruses, because viral RNA polymerases
lack the proof-reading ability of DNA polymerases. This
property raises the difficulty in producing effective vac-
cines. It must also be noted that errors during reverse
transcription are embedded into both strands of the
intermediate viral DNA before integration into the host
DNA, which can cause changes in the transcription-
translation of the host cell functional household protein
constituents, and consequential significant alterations in
the host cell structure and function in its natural micro-
environmental milieu. In the case of EBOV, the virus
infects the myeloid population, and it is to be expected
that EBOV-infected macrophages and dendritic cells
may have structural and functional alterations that may
impair their role in cell-mediated immunity and antigen
presentation (vide infra).
The Filoviridae consist of three genera: cuevavirus,
marburgvirus, and ebolavirus (EBOV). Five species of
EBOV are now known, and four of these cause Ebola
virus disease (EVD) in humans [4,5]. The five known
species of EBOV are named for the region where each
was originally identified:
 Bundibugyo virus: On the 24th of November 2007,
the Uganda Ministry of Health confirmed an
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following confirmation of samples tested by the US
National Reference Laboratories, CDC and WHO.
On the 20th of February 2008, the Uganda Ministry
officially announced the end of the epidemic in
Bundibugyo, with the last infected person
discharged on the 8th of January 2008. An
epidemiological study conducted by WHO and
Uganda Ministry of Health scientists determined
there were 116 confirmed and probable cases, with a
mortality rate of 34%.
 Reston virus: Reston EBOV was discovered during
an outbreak of simian hemorrhagic fever virus in
crab-eating macaques from Hazleton Laboratories
(now Covance) in 1989. Since the initial outbreak
in Reston, Virginia, it has since been found in
nonhuman primates in Pennsylvania, Texas, and
Siena, Italy. In all cases, the affected animals had
been imported from a facility in the Philippines,
where the virus has also infected pigs. Despite its
status as a Level‑4 organism and its apparent
pathogenicity in monkeys, Reston EBOV is not
believed to cause EVD in exposed human laboratory
workers. It is the only ebolavirus that is pathogenic
for nonhuman primates, and that is nor originally
endogenous to Africa.
 Sudan virus: Sudan EBOV emerged in 1976, and was
at first assumed to be identical with the Zaire
species. It is now thought that this species broke out
first amongst cotton factory workers in Nzara,
Sudan (today South Sudan). The first case reported
was a worker exposed to a potential natural
reservoir, although the original carrier remains
unknown. The most recent outbreak occurred in
August, 2014, when 13 cases were reported in Djera,
Democratic Republic of Congo. The fatality rates for
Sudan ebolavirus are variable, ranging from 54% in
1976, 68% in 1979, to 53% in 2000 and 2001.
 Taï Forest virus (i.e., Côte d’Ivoire ebolavirus): This
species of EBOV was first discovered among
chimpanzees from the Taï Forest in Côte d’Ivoire,
Africa, in 1994. Necropsies showed blood within the
heart to be brown; no obvious marks were seen on
the organs; and one necropsy displayed lungs filled
with blood. Taken together, this symptomatology is
suggestive of tissue hypoxia secondary to
methaemoglobinaemia, a blood disorder
characterized by the presence of a higher than
normal level of ferric [Fe3+] rather than ferrous
[Fe2+] hemoglobin. Ferric hemoglobin has increased
affinity for oxygen but reduced ability of the red
blood cell to release oxygen to tissues, compared to
the normal ferrous hemoglobin. Consequently,
methemoglobin concentration is elevated, the bloodappears oxidized and acquires a deep red-to-brown
color, and tissue hypoxia occurs. At elevated
concentrations, methemoglobin can cause coma and
death; at intermediate concentrations (about 50%),
it contributes to headaches, confusion, agitation
and related behavior problems; even at lower
concentrations (below 30%), methemoglobin can
contribute to severe alterations and histopathologic
dysplasias of mucous membranes or the oral and the
gastro-intestinal lining. Hemoglobin is also found in
non-blood tissues and cells, such as neurons and
macrophages, where its function is primarily that of
an anti-oxidant. At high concentrations of
methemoglobin, that anti-oxidant protective ability
is lost, placing both neurons and myeloid cells at
higher risk of programmed cell death (i.e.,
apoptosis). Since hemoglobin synthesis begins during
the pro-erythroblast stage of the red blood cell cycle,
EBOV-mediated disruption of the process can lead
to the production of ferric (Fe3+), rather than
ferrous (Fe2+) hemoglobin. The synthesis of the
heme component takes place in the mitochondria
with the condensation of glycine & succinyl-CoA to
form δ-aminolevulinic acid, which then leaves the
mitochondria and forms porphobilinogen, and
eventually coproporphyrinogen. In that form, it
re-enters the mitochondria and becomes
protoporphyrin. Protoporphyrin combines with
iron to form the heme, which now exits the
mitochondria to combine with the globin molecule
produced in the ribosome. Studies of tissues taken
from the chimpanzees showed results similar to
human cases during the 1976 Ebola outbreaks in
Zaire and Sudan. As more dead chimpanzees were
discovered, many tested positive for Ebola using
molecular techniques. The source of the virus was
traced to infected western red colobus monkeys
(Procolobus badius) upon which the chimpanzees
preyed. One of the scientists performing the
necropsies on the infected chimpanzees contracted
EBOV, developed symptoms similar to those of
dengue fever within 7 days, was treated aggressively
and fully recovered within 6 weeks.
 Zaire virus: Zaire EBOV is the type reference for all
species of Ebola virus, since it has a sole known
member - although it is suspected to have the
potential for several mutant forms. Zaire EBOV has
the highest mortality rate of the Ebola virus, with a
case-fatality rate up to 90% in some epidemics, and
an average case-fatality rate of approximately 83%
over 27 years. Zaire EBOV is responsible for the
largest number of outbreaks of the five known
members of the genus, including both the first
documented outbreak in 1976, and the current most
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mistaken for malaria, and the patients received
quinine, with unsuccessful outcomes.
As noted, all EBOV’s are enveloped non-segmented
negative strand RNA viruses characterized [4-6] by:
 A lipid bilayer coat that protects the viral genome
and facilitates host cell entry
 A viral genome with several gene overlaps
 A fourth gene that encodes four proteins that
include
○ soluble glycoprotein, sGP;
○ small soluble glycoprotein, ssGP;
○ Δ-peptide, and
○ viral glycoprotein heterodimer 1,2 (vGP1,2) using
co-transcriptional editing to express ssGP and
GP1,2, and proteolytic cleavage to express sGP
and Δ-peptide
 A peak of infectivity of its virion that is associated
with particles ≈ 805 nm in length
 A genome that differs from that of its related family
member, the Marburgvirus (MBGV), by ≥50%, but
that diverges from the genome of other EBOV
by <50% at the nucleotide level, and
 A set of virions that shows almost no antigenic
cross reactivity with Marburg virions.
The natural reservoir host of Ebola virus remains un-
known. However, on the basis of evidence and the nature
of similar viruses, EBOV is believed to be animal-borne
and that bats are the most likely reservoir. Four of the five
virus strains occur in an animal host native to Africa. Fruit
bats of the Pteropodidae family are the most likely natural
ebolavirus hosts. Bats and other wild animals drop par-
tially eaten fruits and pulp, and land mammals may feed
on these fallen fruits, thus initiating the EBOV-infected
food chain that leads to human consumption.
In brief, it is believed that Ebola is introduced into the
human population through close contact with the blood,
secretions, organs and other bodily fluids of infected ani-
mals such as the fruit bats, chimpanzees, gorillas and
other monkeys, forest antelope and porcupines, which all
have been found ill or dead with signs akin to EVD in the
rainforest. Fruit production, animal behavior, as well as
other indigenous factors of sub-tropical Africa that vary
from year to year and in different seasons and places may
contribute to trigger outbreaks of the different EBOV spe-
cies among animal populations and humans, although no
clear corollary relationships have been uncovered to be
predictive of Ebola outbreaks [1,2].
Whereas EBOV is acquired upon contact with blood
or bodily fluids of infected animals, it is then thought to
spread through human-to-human transmission only viadirect contact (through broken skin or mucous mem-
branes) with blood, secretions, or other bodily fluids of
infected people, and possibly with surfaces and materials
(e.g. bedding, clothing) contaminated with these fluids.
In addition, traditional caregiving, which may engage
physical contact and touching, and burial ceremonies
during which mourners have direct contact with the
body of the deceased person are thought to play an im-
portant role in the transmission of Ebola (vide infra) [1].
At this time, and based on the epidemiological pat-
terns of previous outbreaks, it is not believed that the
virus can be contracted by aerosol, although the specter
of mutated EBOV that could be airborne is a distinct
possibility, if not a statistical probability. The aggressive
nature of the outbreak presently in course seems to
suggest that the current species of EBOV may in fact
already have mutated and evolved into a more virulent
form than originally expected, with contagion potential
beyond exposure to body fluids of patients actively
showing symptoms, as Richard E. Besser, MD, former
CDC acting director, suggests. It is possible, he and
others at CDC argue, that the Ebola virus could already
spread “…through the air in tight quarters…”; and Tim
Skinner, CDC spokesman, added that CDC is presently
exploring whether and how the US should modify its
policy to face this world-wide health threat. The contri-
butions of environmental factors to EBOV transmission
are not fully understood to this date. It is, therefore,
most appropriate for CDC to emphasize the importance
of avoiding “…contamination of reusable porous surfaces
that cannot be made single use. Use only a mattress and
pillow with plastic or other covering that fluids (sic) can-
not get through. Do not place patients with suspected or
confirmed Ebola virus infection in carpeted rooms and
remove all upholstered furniture and decorative curtains
from patient rooms before use. To reduce exposure
among staff to potentially contaminated textiles (cloth
products) while laundering, discard all linens, non-fluid-
impermeable pillows or mattresses, and textile privacy
curtains into the waste stream and disposed of appro-
priately…” [1,2].
Moreover, it is widely believed that transmission of
EBOV can only occur from a patient who clearly mani-
fests symptoms [1,2]; however, “…there is no proof that
a person infected – but lacking symptoms – could not
spread the virus to others…” (David Willman, Ebola ex-
perts urge greater caution, Los Angeles Times, Tuesday
October 7, pp. A1 & A10). In fact, the rationale for this
position, strictly on immunopathological grounds is
unclear at best and at worst categorically unfounded.
The statement is apparently based on the findings ob-
tained from the previous outbreaks. Nonetheless, scant
data are available to generate statistical inference of
sufficient power to warrant such assertion. In brief, it is
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and statistical evaluation of the evidence, that EBOV is
contagious well before symptoms are noted. This, in
and of itself, may contribute to explain why the current
outbreak is aggressively advancing beyond our compre-
hension and expectation. Indeed, EBOV+ survivors are
infectious as long as their blood and body fluids, inclu-
ding semen and breast milk, contain the virus [1],
whether or not they manifest obvious and evident symp-
toms. Male survivors seem to be able to transmit the
disease via semen for nearly two-to-three months fol-
lowing the date they are declared “cured”.
Based on the observations gathered during the pre-
vious outbreaks, it is believed that EBOV is sensitive to
heat and chemical denaturation. Common expectations
are that it can be degraded by heat (30–60 minutes at
60°C or boiling for 5 minutes), or by some lipid sol-
vents (e.g., alcohol-based products, detergents, sodium
or calcium hypochlorite). But supportive evidence
across the recognized EBOV species is not compelling
to this date. Evidence suggests, by contrast, that EBOV
may have remarkable resistance. The virus is suspected
to survive on hard and porous surfaces soiled with body
fluids of EBOV+ patients, such as bedding, clothes,
walls and other planes, for several days. To cleanse
EBOV-contaminated requires extensive washing with
chlorine and ethanol diluted in clean uncontaminated
water (i.e., one part chlorine, one part ethanol, nine
parts clean - possibly distilled or double-distilled -water).
It is in part for these reasons, that the dearth of clean
water remains a critical impediment in slowing the out-
break and bringing about an effective medical response in
West Africa [6,7].
Quarantine, which is nothing but enforced isolation,
is currently the most effective mode of decreasing the
spread of this disease. Households, schools, localities,
villages, town, cities or entire regions may be lawfully
isolated where the disease is occurring or believed to
occur, or individuals putatively infected may frequent.
In this fashion, Senegal recently declared itself a
“Ebola-free” country. Contact tracing is an important
approach, perhaps one of the most effective public
health protocols to contain an outbreak. Contact tra-
cing permits to find everyone who has had close con-
tact with infected individuals and watching for signs of
illness. If any of these contacts come down with the
disease, they should be isolated, tested, and treated, and
their contacts traced and followed. The process is sys-
tematically repeated by tracing the contacts’ contacts. It
is clear that contact tracing is feasible and efficient only
when the number of cases is small or limited; as an
epidemic grows, contact tracing evidently takes an
increasingly prohibitive amount of time and manpower
to run.From epidemic outbreaks to pandemic threat
Ebola pathology
Ebola virus disease (EVD), Ebola hemorrhagic fever
(EHF), or simply Ebola is a disease of humans and other
primates caused by EBOV. Symptoms of Ebola can start
2–21 days following initial contact with the virus. Initial
manifestations include a sharp rise in fever, sore throat,
muscle pain and headaches. Explosive vomiting and
diarrhea soon follow, which, if left untreated, lead to
serious dehydration, dizziness, confusion, kidney and liver
failure, and eventually complete physiological collapse.
Skin rash and eruptions appear, which soon develop into
bleeding infected ulcerations. Extensive internal and exter-
nal bleeding from the orifices (i.e., eyes, nose, ears; bloody
diarrhea and urine), and signs of internal hemorrhage,
including alterations in the integrity of the blood–brain
barrier (BBB) (Brakhordarian et al., in press), contribute to
the profuse and cascading loss of micronutrients. Labora-
tory findings confirm low white blood cell and platelet
counts, and elevated liver enzymes.
The general symptomatic profile of EVD resembles
that of other viral hemorrhagic fever (VHF) diseases
[6,8-10], including dengue (Chiappelli et al., Bioinforma-
tion, in press). Consequently, the diagnosis for EVD can
be complicated and relatively slow, because several of its
symptoms overlap with malaria, cholera, dengue, and
other VHFs. Expectations are, in fact, that, as the present
Ebola epidemic continues to grow, it may eventually
shut down malaria and dengue control efforts on the
African continent. Case in point, the present outbreak
has virtually hampered malaria control efforts in Liberia,
Guinea and Sierra Leone, raising fears that cases of the
mosquito-borne illness will soon rise because routine
health care in the affected countries has all but collapsed
(Thomas Teuscher, acting executive director of Roll
Back Malaria Partnership). As a result, and in part be-
cause the early symptoms of Ebola mimic the symptoms
of malaria, tens of thousands of people are erroneously
be given antimalarial medication, which can induce drug
resistance to the parasite that causes the disease in
malaria-free individuals, and deplete the available doses
of anti-malaria medicine. Misdiagnosis and mistreatment
may thus not only delay prompt intervention in EBOV+
patients, but also contribute to the resurgence of malaria
in Africa and globally. Indeed, people who are free of
Ebola are at higher risk for malaria in West Africa pre-
sently, as noted by Estrella Lasry, MD, tropical medicine
specialist for Médecins sans Frontières.
Patients with severe hemorrhagic disease, such as
Ebola or dengue produce dangerously high levels of in-
flammatory cytokines, which destroy normal tissue and
microcirculation, leading to profound capillary leakage,
renal failure, and disseminated intravascular coagulation.
For the discriminant diagnosis of Ebola, malaria and
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the diagnosis of EVD must then be confirmed by ana-
lysis of blood samples, and possibly other body fluids
including saliva, for EBOV antibodies, EBOV RNA, or
EBOV itself [1]. Taqman-RT-PCR protocols for the de-
tection of the various species of EBOV, including Zaire-
EBOV, were developed and established on a portable
Smartcycler-TD over a decade ago [11,12]. However, the
use of this technology is often not feasible on the ground
and in field hospitals of isolated villages or localities of
West Africa. Confirmation of EBOV infection can also
be obtained by electron microscopy, and virus isolation
by cell culture [1]. To confirm Ebola cases, samples must
be shipped to a testing site; however, considering the
high infectivity of these samples, shipping operations
such as these are of very high risk.
Proteomic signature
Genomic and proteomic advances now proffer some de-
gree of understanding of the EBOV virion. Data propose a
minimal gene set that can distinguish between EVD sur-
vivor and non-survivor non-human primate experimental
animals under specific anticoagulant treatment conditions.
In a recent study of 23 rhesus macaques: 19 treated with
anticoagulant therapeutics (11 with recombinant human
activated protein C, and eight with recombinant nematode
anticoagulant protein – of these animals, four of the
treated, two in each group, survived a lethal challenge
with EBOV [H.sapiens-tc/COD/1995/Kikwit-9510621])
and four untreated controls, the findings of transcripts
micro-analyses revealed that there might be few genes that
could be identified as prognostic biomarkers of survival
[13]. Analysis of mRNA expression changes between
treated EVD survivors and treated/untreated non-survivors
further revealed 20 unique identified probes (16 annotated
genes, three genetic loci, one microRNA) that distinguish
EBOV-challenge survivors from non-survivors. By means
of the statistical technique of hierarchical clustering and
leave-one-out cross-validation, the minimal gene set could
be correctly classified with nearly 100% accuracy [13].
Specifically, the data pointed to:
 The up-regulation of six genes
○ ACCN1, Amiloride-sensitive cation channel
neuron 1, a member of the degenerin/epithelial
sodium channel superfamily that contributes to
the regulation of neurotransmission.
○ CEBPE, CCAAT/enhancer binding protein-ε, a
pro-apoptotic gene product that is essential for
terminal differentiation and functional maturation
of committed granulocyte progenitor cells
(a defect, or decrease in this gene product resulting
in granules deficiency, and impaired functional
myeloid differentiation and maturation [14].○ CRHR2, Corticotropin releasing hormone
receptor 2
○ FAM63A, putative cytoskeletal protein
○ HMP19, Neuron-specific protein family
member 2
○ IL2RA, Interleukin-2 receptor-α, CD25
○ LTF, lactoferrin of the transferrin family, a
80 kDa glycoprotein widely represented in body
fluids (i.e., milk, serum, saliva, tears, nasal
secretions), as well as secondary granules of
granulocytes and other myeloid cells, and as
such an essential component of cellular
immunity. Whereas administration of lactoferrin
has been shown to be beneficial in reestablishing
physiological homeostasis of iron metabolism in
an experimental model of hemorrhagic disease
in rodents [15], the putative palliative role of
lactoferrin administration in hemorrhagic EVD
remains to be examined.
○ PSMA1, Proteasome subunit alpha type-1, a
multi-catalytic proteinase complex in
proteasomes, which cleaves peptides in an
ATP/ubiquitin-dependent process in a
non-lysosomal pathway.
○ RCHY1, RING finger and CHY zinc finger
domain-containing protein 1 that has
ubiquitin-protein ligase activity, and binds
with p53 and promotes the ubiquitin-mediated
proteosomal degradation of p53, thus being
oncogenic in nature.
○ SLC9A7, solute carrier family 9, subfamily A,
member 7, a Na/K proton antiporter, member of
the solute carrier family 9 protein family, that is
primarily localized to the trans-Golgi network
and is involved in maintaining pH homeostasis
in organelles along the secretory and endocytic
pathways.
 The down-regulation of 10 genes
 The following genetic loci
○ AC009283: chromosome 17
○ LOC100289371: mitochondria-encoded
cytochrome c oxidase III pseudogene,
chromosome 5
○ LOC440871: chromosome 2
 microRNA (miR-122), a known positive regulator of
viral replication for hepatitis C virus [16] and in fact
a biomarker of neuroinflammation in patients with
chronic hepatitis C virus [17] – indeed, preliminary
trials show that miravirsen, the Santaris Pharma
locked nucleic acid-based antisense oligonucleotide
that can delivered to the liver to effectively inhibit
miR-122 following intravenous injection without
liver toxicity, significantly reduces reduced
hepatitis C virus viremia in non-human primates
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experimental RNA therapy, in EBOV-infected
patients, albeit seemingly promising [19], has not
commenced as of this date.
In the transcriptomic analysis of EBOV-challenged non-
human primates study noted above, overall, survivors ex-
hibited “significant and opposing regulation of expression”
when compared to non-survivors, without regard to whe-
ther the non-survivors received anticoagulant or not. Spe-
cific analysis of the identified genes suggested that genes
associated with cellular immune and inflammatory re-
sponses were up-regulated in non-survivors, consistent
with the hypothesis that non-survivors experience acute
deregulation of cellular immune surveillance [13] (vide
infra). It is possible and even probable that future investi-
gation of these pathways could reveal transcriptional sig-
natures specific to EBOV infection and host immune
response.
Rather than the more invasive technique of collecting
blood for measuring EBOV, saliva was established in
earlier studies to be potentially useful and promising for
the investigation of Ebola epidemics and pandemics. In
those studies, anti-EBOV immunoglobulin G antibodies
could not be detected in the saliva of patients who had
elevated levels of serum anti-EBOV immunoglobulin G
antibodies by enzyme-linked immunosorbent assay. By
contrast, both salivary and serum samples from these
patients exhibited positive serum RT-PCR for EBOV
[12]. Transcriptomic analysis of the type described above
must now be performed on salivary samples, in order to
maximize utilization of this body fluid for the purpose of
fast, sensitive and reliable diagnosis EBOV infection.
For the time being, no specific treatment for EVD dis-
ease is available, in part because of the complex, multi-
step and highly orchestrated path of internalization and
fusion of the Ebola virus. Cellular entry of EBOV requires
a series of cellular protein interactions and molecular
mechanisms, which commence with the interaction of the
heavily glycosylated viral glycoprotein, GP1,2, with both
adherence factors, such as the Δ-peptides and receptors
on the surface of host cells, such as the T cell immu-
noglobulin and mucin domain 1 (TIM-1) on epithelial
cells. Upon receptor binding, the virus is internalized into
endosomes primarily via macro-pinocytosis. The acidified
endosomal cellular proteases Cathepsin L and B cleave
GP1,2, and expose residues in the receptor binding site.
These viral residues interact with endosomal/lysosomal
membranes that contain the Niemann Pick C1 like pro-
tein [19]. Indeed, Niemann Pick C1 protein expression is
required for productive EBOV infection. That the drug
ezetimibe blocks Niemann Pick C1 like protein [20] seems
to suggest that it might well contribute to blunt produc-
tive EBOV infection. However, this treatment option hasnot been examined in EVD patients at this time. Certain
novel drugs are undergoing testing, such as the human im-
munodeficiency virus-inactivating protein cyanovirin-N,
which binds to vGP1,2, and inhibits infectivity of Ebola
virus [21,22].
Medical anthropology
There are certain requirements that must be met when
attempting to prevent EVD epidemics to burgeon into a
pandemic threat, and which can be summarized as follows:
1. correct the deficiency in the development and
implementation of surveillance response systems
against Ebola specifically, and others infectious
disease outbreaks in Africa more generally, by means
of a well coordinated program of evidence
dissemination such as that we proposed in
translational science for evidence-based health care
dissemination [23-25],
2. correct the lack of education and knowledge
resulting in an EVD outbreak, which contributes to
trigger panic, anxiety, psychosocial trauma, isolation
and dignity impounding, stigmatization, community
ostracism and resistance to associated socio-ecological
and public health consequences, by utilizing
dissemination efforts toward increasing health
literacy [25,26];
3. correct the limitations in financial resources, human
technical capacity and weak community and
national health system operational plans for
prevention and control responses, practices and
management;
4. correct the inadequate leadership and coordination; and
5. correct the lack of development of new strategies,
tools and approaches, such as improved diagnostics
and novel therapies including vaccines, which can
assist in preventing, controlling and containing
Ebola, by emphasizing evidence-based,
patient-centered and effectiveness-focused
concerted interventions [27].
As noted above, Ebola is caused by one of five identi-
fied EBOV viruses, and is highly contagious. Human-to-
human transmission can occur via direct contact with
blood or bodily fluids from an infected person, including
touching during caregiving, embalming of an infected
dead person, contact with the corpse during burial, or
handling personal objects of the Ebola victim conta-
minated by the virus, particularly bedding, clothing, nee-
dles and syringes [28].
Epidemiologic transitions and zoonotic threats
The “third epidemiologic transition” is characterized by
an unprecedented number of novel diseases detected
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and prevalence of pre-existing infectious diseases that
were thought to be under better control” ([29], p. 256).
Many emerging pathogens are generating antibiotic resis-
tance, and some are multi-drug resistant. All of this occurs
“within the broader context of globalization, involving
international trade, migration, information networks, and
the convergence of human disease ecologies” ([29], p. 257).
Disease pathogens, as with Ebola, “are often provided the
opportunity to jump the ‘species barrier’ by a combination
of ecological disruption and increased contact between
humans and wild reservoir species. The size and mobility
of human populations increases the potential for the
pathogen to escape its geographic barrier” ([29], p. 259),
and is complicated by the widening of inequalities within
and between societies increases the spread of emerging
and reemerging diseases [30]. Most pathogens in humans
are zoonotic in origin. Population, ecological, and beha-
vioral alterations that increase contact with wildlife inten-
sify the emergence of these pathogens. Anthropogenic
environmental modification has altered the risk of zoo-
notic infection from wildlife. Ebola exemplifies how
anthropogenic factors facilitate pathogen transmission
between human and nonhuman animal populations [31].
Emerging infectious diseases (EIDs) of free-living wild
animals are “associated with ‘spill-over’ from domestic
animals to wildlife populations living in proximity; and
human intervention via host or parasite translocations”
([32], p. 443). The increasing populations of domestic ani-
mals, especially in feedlots, with close and constant con-
tact with wildlife contribute to transmission. As a result,
many wildlife species are reservoirs of pathogens that
threaten the health of domestic animals and humans. Dis-
ease emergence most frequently results from a change of
ecology of host and pathogen, or both. Human population
expansion has driven the emergence of EIDs through in-
creasing population density, especially in urban areas, and
encroachment in to wildlife habitat. Human encroach-
ment on shrinking wildlife habitat has also caused in-
creased wildlife population densities and the emergence of
wildlife EIDs. Wild animals play an especially important
role in EID emergence by “providing a ‘zoonotic pool’ from
which new pathogens can emerge” ([32], p. 446). Un-
derstanding how environmental change alters the contact
between human and non-human primates, thereby in-
creasing the possibility of sharing infectious diseases detri-
mental to humans or nonhuman primates, is essential to
global health planning. Diseases like Ebola devastate both
human and wildlife communities, with outbreaks of the
virus tracing their origins to zoonotic transmissions from
local apes, especially since monkeys and apes often share
parasites with humans [33]. However, human displace-
ments of fruit bats through deforestation make this a vec-
tor species for transmission of Ebola, as well.Human-animal entanglements
Human-animal “entanglement” focuses on the ways in
which disease, instead of alienating humans from other
life forms, brings their intimate relationships into
sharper relief [34]. As such, people, animals, “pathogens
and spaces are connected in a process of ‘mutual beco-
ming’” ([34], p. 69). Health thus becomes the locus for
critically analyzing “the production of life, where life is
the ongoing, dynamic result of human and nonhuman
interactions over time” ([34], p. 60). Studies of EIDs,
such as Ebola, bring human and nonhuman animals to-
gether within a framework that examines “how anthropo-
genic landscape change leads to ‘disease emergence’” ([34],
p. 69). An example of such entanglement is bush meat
hunting, which has brought about “unsustainable and
increasing rates of harvesting, leading to the ‘empty forests’
of parts of Africa” ([35], p. 366). EIDs, such as Ebola,
which have the highest fatality rates, have emerged from
wildlife. Moreover, the causes of their emergence are
clearly linked to the way in which humans interact with
wildlife, through encroachment, road building, defores-
tation, hunting and the global trade in them. The recent
interest in the underlying causes of zoonotic disease emer-
gence, namely changes to human demography, behavior
and the environment, denotes a shift in tropical medicine,
from reactive to proactive approaches. An anthropology of
viral hemorrhagic fevers (VHFs) focuses on “the hotspot”
to understand the “two routes of VHF infection: from ani-
mal reservoirs to humans and between humans” ([36], p.
280). Through this perspective, human–animal entangle-
ments are viewed in terms of the social production of
space to understand viral movement by elaborating the
circumstances through which viruses, humans, objects,
and animals come into contact. The “material proximities
between animals, humans, and objects that constitute the
hotspot,” ([36], p. 280) can establish an epistemological
“frontier” for collaborative efforts between anthropologists
and other scientists on behalf of VHF management and
control.
Ebola through an anthropological lens
Anthropological studies in these hotspots aim at under-
standing local views and responses to an outbreak. In
experiencing Ebola, local people employ multiple ex-
planatory models to make sense of and respond to the
outbreak; their indigenous epidemic control measures
are often implemented and these are consistent with the
ones being promoted by healthcare workers; although
some cultural practices, such as burial practices, amplify
the outbreak [37]. How local people in Gabon viewed
Ebola and responded to the rapid killer during outbreaks
in the 1990s, and how they view the international health
care worker teams mobilized to help control the disease
are key concerns in understanding subsequent outbreaks
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to flee the area are human universals. Local people in
village communities invoked sorcery and consulted in-
digenous healers as they attempted to understand and
explain the disease. At first, they questioned why par-
ticular individuals were infected with Ebola, and later as
the epidemic progressed, why the virus emerged in their
country, noting the impact of European imperial en-
croachment on and “poisoning” of the forest. Local
people also worked to help control the outbreak by iso-
lating infected people or limiting their contacts, kept
children away from the sick, and sought treatment from
indigenous healers and government health care workers.
Localities in Gabon also felt exploited by international
health workers who passed through villages to draw
blood, and who not only failed to compensate or report
findings back to village communities, but also showed
scant compassion or empathy for villagers’ expressions
of loss of their loved ones.
The primacy of caring
Efforts to control high mortality diseases, such as Ebola,
provide two distinct but complementary interventions
during the first phases of an outbreak in the Republic of
Congo [39]. The first approach emphasized understand-
ing local people’s cultural models and political-economic
explanations for the disease while the second approach
focused on providing more humanitarian care of patients
by identifying and incorporating local beliefs and prac-
tices into patient care and response efforts. The expe-
riences of health care workers during Ebola outbreaks in
Uganda in 2000–2001, Republic of the Congo in 2003,
and Democratic Republic of the Congo in 1995 included:
a lack of protective gear, basic equipment, and other
resources necessary to provide care, especially during
the early phases of the outbreaks; and stigmatization by
family, coworkers, and community [40]. Improving treat-
ment of VHFs in sub-Saharan Africa ultimately hinges
on effective and compassionate care for the effected pa-
tient. To this end, there is the need to refocus efforts on
aggressive supportive care and clinical monitoring; in-
cluding communications and social mobilization experts
as a primary part of every outbreak response team; and
reestablishing the isolation ward as the key functional
component of the overall outbreak control strategy [41].
The response efforts of Médecins sans Frontières, to-
gether with WHO, and the government health ministry
to contain a VHF epidemic in Angola offer insight into
care for those infected included “community epidemio-
logical surveillance, clinical assessment and isolation of
patients, safe burials and disinfection, home-based risk
reduction, peripheral health facility support, psychosocial
support, and information and education campaigns”
([42], p. 162). The key lesson learned is that containmentof the Angolan epidemic depended on the collaboration of
the affected community; a critical factor being active in-
volvement of all stakeholders at the start of the outbreak
response. In an attempt to understand social responses to
a major Ebola outbreak in Uganda in 2000–2001, in local,
national, and international contexts, over the course of
the outbreak, a content analysis was conducted using arti-
cles, editorials, cartoons, and letters to the editor from the
country’s two main English language newspapers [43]. Key
themes were:
 social psychological responses, such as confusion,
anger, and serious stigma;
 overworked medical personnel, accompanied by
burnout;
 patients fleeing from hospitals;
 invocation of spiritual forces;
 varieties of national control strategies; and
 precautionary measures, such as international travel
restrictions.
VHF outbreaks in Africa can be seen as a paradigm for
ethical issues posed by epidemic emergencies, including
isolation and quarantine; privacy and confidentiality; and
the interpretation of ethical norms across different eth-
nocultural settings, especially research ethics [44]. While
informed consent and institutional review processes go-
verning collection of biological samples and epide-
miological data are regulated by national guidelines and
international conventions, there remains a need for new
ethical frameworks on behalf of engaging potentially af-
fected communities in research design and in the commu-
nity permission process during an outbreak.
Framing Ebola: competing perspectives & the politics of
knowledge
Four “narratives” about VHF frame the debates sur-
rounding “cultural models” of risk and vulnerability; the
intersection of social, ecological and disease processes;
and the discourse on local knowledge [45]:
 the first concerns VHFs as an emerging global problem;
 the second views the problem as a deadly local
disease requiring rapid mobilization and
containment;
 the third understands local knowledge and
socio-cultural practices as necessary to informing
explanatory models of VHFs; and
 the fourth addresses longer term social and
environmental interactions involved with disease
patterns and vulnerabilities.
Together, they help shape “contrasting institutional
and policy pathways” for responding to VHFs. Hence,
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and policy challenges optimally met by complex modeling
approaches of epidemiological, ecological and social pro-
cesses. Moreover, the models, themselves, have “social and
political lives,” because of the norms and values embedded
in their design and intent [46]. Ebola, especially because of
the fear of widespread contagion and death, provides a
way to understand how the social and political lives of a
zoonotic disease model can be co-constructed, scien-
tifically and politically, with particular policy interests in
mind.
Biosocial approaches
Outbreaks of Ebola remind us of the need for models of
disease emergence that are “dynamic, systemic, and cri-
tical”; models that “incorporate change and complexity,
and are global yet alive to local variation,” account for
social inequalities, and then question “how large-scale
social forces influence unequally positioned individuals
in increasingly interconnected populations” ([47], p. 259).
Regarding the interplay of culture and ecology in the
epidemiology of infectious disease, behaviors related to
diet, activity patterns, water use, and sexual practices
that predispose individuals to certain diseases might be
shaped by culture ([48], p. 254). While cultural practices,
including agriculture and warfare, provide the means for
people to actively transform their environments, these
can also affect their susceptibility to infections. Cultural
models of etiology, patient role and treatment influence
how people respond to the illness ([48], p. 254). Human
biosocial factors clearly have an impact on R0, the basic
reproductive rate of a pathogen, or the expected number
of infections caused by one infected individual in a sus-
ceptible population. “All three components of R0 (contact
or exposure rates, probability of transmission, and du-
ration of infection) are partly regulated socially” ([49],
p. 1885). Social relationship patterns drive contact rates,
and are themselves related to norms of social affiliation.
Social disparities affect “susceptibility to, and severity
and duration of, infections as a result of psychosocial
stress and risk for co-infection” ([49], p. 1885). Social
processes are central to causal complexes, including
agricultural development and changing land uses, which
increase vector-borne disease risk; together with “the
emergence of viral zoonoses; and social and economic
activities, such as gathering of fruits, handling of bush
meat, and rearing of animals, which bring people closer
to natural or amplifying hosts, or their tissues” ([49],
p. 1885).
Critical medical anthropology
The term “syndemic,” is used to label the synergistic
interaction of two or more coexistent diseases and re-
sultant excess burden of disease within the context ofstructural factors [50]. A syndemical research framework
attempts to explain co-infection and synergistic inter-
action of diseases and social conditions at the biological
and population levels, especially with infectious diseases,
“their entwinement with each other, and with the social
conditions and bio-psychological consequences of disparity,
discrimination, and structural violence” ([50], p. 423). The
syndemic concept has been expanded to include how
animal health and human health connect as “one health,”
especially in prevention, where animal and human
diseases, together with environmental degradation are
influenced by social conditions and political economic
arrangement [51]. While infectious disease epidemics re-
sult from long-term and complex social, ecological, eco-
nomic and political processes, outbreaks are experienced
“on the ground” as unexpected eruptions [52]. The dia-
lectical relationship between the outbreak as an event and
a process provides an opportunity to analyze epidemic
temporality in the context of emergent infectious disease
discourse and intensifying bio-political surveillance aimed
at averting the “next pandemic.” This dialectic between an
event and a process resides at the interface of states and
markets as seen in the borderland of Uganda and the
Democratic Republic of the Congo after an Ebola out-
break in 2008 [53]. Border conditions, in this case, under-
score the centrality of the reconstructed “post-conflict
state” as it attempts to regulate political space and restore
regional economic development in the aftermath of an
outbreak and regional civil warfare. Efforts to regulate na-
tional border traffic and commerce invariably met with
entrenched forms of formal and “informal” economies,
and often illegal trade in minerals and bio-resources by
ordinary people engaged in cross-border commerce, many
of whom viewed the reconfigured state as predatory.
Cross-border trade and economies were disrupted, first by
disease and warfare, and then by what was perceived, on
the ground, as an attempt by “the predatory state” to regu-
late the everyday lives of localities and their citizens, who
despite these disruptions, prevailed in reconstituting local
markets based upon traditional livelihood practices. Only
by considering both the activities of the state and the be-
haviors of the pathogen, in other words bringing together
the macro- and micro-levels of analysis, can we under-
stand an infectious disease like Ebola.
Biosecurity
The intersection of national security and public health in
recent decades has brought about a reframing of the threat
of infectious disease, from prevention to preparedness [54].
The norm of preparedness, used throughout the post-war
decades in military and civil defense contexts, has migrated
to governmental public health intervention. With this
move, widespread public discussion of biological threats
has focused on expert techniques, such as the scenario-
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gency, absent the event itself, and knowledge about vulner-
abilities in response capability, on behalf of intervention
design. With the shift from population-based risk calcula-
tions to a focus on preparedness through scenario-based
projections, “health” and “security” now shape biosecurity
debates, including emergency management [55]. However,
a key focus of the biosecurity discourse, that of “com-
munication,” has not been fully conceptualized. “Bio-
communicability” is a term used to indicate the cultural
modeling of how this discourse is produced, circulates, and
is received. Biosecurity is also an “object in the making”
([56], p. 1) under post-Cold War globalization, as it informs
questions of global health, capitalism, neoliberalism, hu-
manitarianism, citizenship, science, medicine, technology,
ecology, surveillance, and risk. Recent ethnographies detail
the ways “actors and institutions in the Global North and
the Global South” ([56], p. 1) view both biological risks and
the spread of dangerous biological entities that threaten in-
dividual and population health. Hence, a new “landscape”
of global health policy and practices has transformed infec-
tious disease prevention and control. This reconfiguration
of “institutions, technologies and financial flows” ([57],
p.199) includes framing of health as a security issue; the
emergence of new global regimes and organizational as-
semblages focusing on specific infectious threats; the
growth of humanitarian medicine; investments by global
philanthropy in development assistance for health, espe-
cially in Africa, and the global trade in pharmaceuticals.
These trends impact health ministries, as they interact with
bilateral and non-governmental aid organizations, often
through public-private partnerships. The resulting man-
dated managerial mechanisms to track funds, together with
monitoring and evaluation protocols, are indicative of
broad neoliberal reforms in the global health sector.
Ebola pathology
Molecular pathology
Ebola hemorrhagic fever is a severe viral infection with
fulminating pathology characterized by fever, shock and co-
agulation defects. Endothelial cells, macrophages, mono-
cytes, and liver cells are the main targets of infection.
Following infection by the virus, a secreted glycoprotein
(sGP) known as the Ebola virus glycoprotein (GP) is syn-
thesized. Ebola replication overwhelms protein synthesis
of infected cells and host immune defenses. The GP forms
a trimeric complex, which binds the virus to the endothe-
lial cells lining the interior surface of blood vessels. The
sGP forms a dimeric protein that interferes with the sig-
naling of neutrophils, allowing the virus to evade the im-
mune system by inhibiting early steps of neutrophil
activation. Neutrophils also serve as carriers to transport
the virus throughout the entire body to places such as the
lymph nodes, liver, lungs, and spleen [57].EBOV infects dendritic cells, which in turn disables the
interferon system and disrupts henceforth the host
antiviral immune surveillance response [58,59]. Almost
contemporaneously, the virus targets myeloid cells (i.e.,
monocytes/macrophages) and induces alterations in the
blood clotting pathway, which together lead to significant
increase in pro-inflammatory cytokines, including IL6,
IL1-β and TNF-α, as well as nitric oxide, which damages
the lining of blood vessels [60]. The virus operates in a se-
quential fashion by first disabling the immune system,
then the vascular system, during which observed symp-
toms can include hemorrhage, hypotension, drop in blood
pressure, and catastrophic organ failure. These symptoms
are usually followed by shock and death.
After infection, IL10 levels were significantly elevated at
the earliest times of infection in pediatric patients who died.
The role of IL10 in inhibiting antigen-stimulated T cell pro-
liferation supports the assumption that a T cell–mediated
response is critical for survival during EVD. Levels of
soluble intracellular adhesion molecule (sICAM) 1, and sol-
uble vascular cell adhesion molecule (sVCAM) 1 for chil-
dren are normally higher than for adults, and the levels that
reported in surviving pediatric patients were consistent
with these normal levels. Pediatric patients who died had
sICAM and sVCAM levels 2–3 times above the reference
range 0–10 days after symptom onset, but these levels
dropped to within the reference range at 11–15 days. This
pattern may reflect early excessive, and ultimately detri-
mental, endothelial activation in these patients. Consistent
with this hypothesis are the increased plasminogen activa-
tor inhibitor 1 (PAI-1) levels also seen in pediatric patients
who died; endothelial cells in response to activating cyto-
kines release PAI-1. An overactive endothelial response, as
evidenced by elevated sICAM, sVCAM, and PAI-1 levels,
may be associated with death in children and adolescents.
However, adult patients typically do not seem to be affected
by this phenomenon. Elevated PAI-1 levels in pediatric pa-
tients with hemorrhagic manifestations likely represent the
overactive endothelium and not a functional inhibition of
fibrinolysis, since PAI-1 activity is likely to be low, as it rap-
idly converts to the inactive form under physiologic condi-
tions. In brief, Ebola-surviving pediatric patients tend to
have higher levels of the chemokine regulated on activation,
normal T cell express and secrete marker and lower levels
of PAI-1, soluble intracellular adhesion molecule, and sol-
uble vascular cell adhesion molecule than pediatric patients
who died. Adult patients had similar levels of these analytes
regardless of outcome [59,60].
Neurocognitive pathology
EBOV infection includes symptoms such as headache, en-
cephalitis, meningitis, cerebral edema, and seizures, which
indicate the virus involvement in pathology of the central
nervous system (CNS). Owing to the high mortality rates
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term neurological and neurocognitive effects are virtually
non-existent. Nevertheless, news reports have suggested
that EBOV-survivors continue to experience complications
such as headache, weakness, fatigue, sensory changes, and
inflammation of certain organs. While there is evidence to
suspect CNS complications among survivors, this may go
unrecognized or unreported [61]. Considering our current
knowledge of Ebola viral mechanisms, reported compli-
cations from long-term survivors, and knowledge of the
adverse effects of pro-inflammatory cytokines on neuronal
function, three potential contributors to ongoing CNS dys-
function in EBOV survivors are considered below:
1. persistent inflammation of the CNS through the
release of cytokines and chemokines and
recruitment of infected monocytes,
2. disruption of the blood brain barrier (BBB), which
increases its permeability and deregulation of tight
junction proteins, and
3. acquired neurological insults resulting from Ebola
virus infection.
Inflammation and CNS
Ebola virus infection causes the initial activation of mono-
cytes/macrophages, which in turn releases cytokines that
target the vascular system, particularly endothelial cells
[62]. While transient innate immune responses in the
form of cytokines are beneficial to the host, the same es-
sential spectrum of cytokines leads to deregulation of
homeostatic mechanisms, destruction of host tissues and
apoptosis [63]. Transmigration of the Ebola virus into
monocytes/macrophages triggers the increased synthesis
of TNF-α, which induces Ebola virus hemorrhagic fever
and contributes to lymphoid cell apoptosis and marked
inhibition of interferonα/β. Infection also leads to the re-
lease a variety of pro-inflammatory proteins that include
IL1β, IL6, IL8, IL15, IL16, the chemokines macrophage in-
flammatory protein (MIP-1)-α and -β, monocyte chemo-
tactic protein 1 (MCP1), macrophage colony-stimulating
factor (M-CSF), macrophage migration inhibitory factor
(MIF), IFN-γ-induced protein 10 (IP-10), and eotaxin to
name a few [64]. However, monocyte-derived dendritic
cells do not secrete proinflammatory cytokines of TNF-α,
IL1β, IL6, IL10, or IL2, IFN-γ, or IL12 after infection with
Ebola virus, though there are higher levels of certain che-
mokines (notably IL8 and MCP1) [65]. Taken together,
these data indicate that monocytes/macrophage subpo-
pulations release large quantities of both cytokines and
chemokines, whereas there is a selective negative effect of
Ebola virus on the induction of the pro-inflammatory
cytokines by dentritic cells.
In the brain, receptors for IL1β, IL6, TNF-α, IFN-γ
and MCP1 have been the most widely studied in relationto neuropsychiatric and neurological disorders. Cyto-
kines have both atherogenic and prothrombotic effects,
which may directly influence neurological events such as
ischemic stroke or vascular dementia. EBOV produces
coagulation defects via cytokine production that directly
influence the coagulation cascade. IL1β, IL2, IL6, and
TNF-α have been directly implicated in the stimulation
of the coagulation system. Abnormalities of the brain
coagulation system have been implicated in traumatic
brain injury [66].
In rodent brains, the hippocampus and hypothalamus
(areas responsible for learning/memory and body home-
ostasis, respectively) have the highest concentration for
receptors of IL1β, IL2, IL6, and TNF-α, which can be-
come up-regulated during peripheral immune activation
[67]. IL1β is also highly concentrated in cerebrovascular
endothelium, and increase after excito-toxic injury, LPS
challenge, mechanical damage, and ischemia [68]. Injec-
tion of IL-1β into specific brain regions has been found
to exacerbate neuronal damage, regardless of the pri-
mary insult (e.g., trauma, ischemia). In response to in-
jury, IL1β induces microglial proliferation and microglial
expression of IL6, though experimental depletion of IL-6
has been found to protect against the adverse effects of
IL1-β and TNF-α on working memory [69]. These fin-
dings suggest that IL-6 may exacerbate the effects of
IL1β and TNF-α.
IL6 plays a critical role in adult neurogenesis [70], which
is altered in many neuropathological situations like stroke,
status epilepticus, mechanical damage, and Alzheimer,
Parkinson and Huntington diseases, which all share in-
flammation in common [71,72]. IL6 has been thought to
exert neurotrophic effects by preventing oxidative stress
and apoptosis. One study found that inhibiting IL6 or its
downstream JAK/STAT signaling pathway in the orbito-
frontal cortex impaired reversal learning, suggesting that
basal IL6 and JAK/STAT signaling facilitate cognitive fle-
xibility [73].
TNF-α is involved in regulating synaptic transmission
and plasticity in the CNS. Elevations in TNF-α, usually
produced by astrocytes and microglia, are associated
with several neurological disorders, and results in an
inhibitory effect on glutamate transporters, resulting in
increased glutamate concentration in the CNS [74]. This
affects cognitive processes such as learning and memory
[75,76], sleep [77], food and water intake [78].
MCP-1 is a β-chemokine that is expressed during inflam-
mation and which, upon activation of its receptor, CCR2,
can induce chemotaxis of monocytes to inflammatory sites
generated by injury and infectious events [79]. MCP-1 has
been identified as the most potent activator of macrophages
in comparison to other monocyte chemo-attractants, in-
cluding RANTES, MIP-1α, MIP-1β, MCP-2β and MCP-3
[80,81]. MCP-1 levels in the brain and cerebrospinal fluid
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dementia, cerebral inflammation [82-88].
Hence inflammation, mediated in part by chemokine
activity and the release of proinflammatory cytokines,
contributes to the breakdown of the brain microvascular
endothelial cells that constitute the BBB (Barkhordarian
et al., in press) increasing the potential for continued
viral invasion into the CNS. While most studies have
focused on the inflammatory response of microglia and
astrocytes [89-91], perivascular cells also play a key role
in brain inflammation [92]. CNS pericytes are involved
in recruitment of peripheral cells to the brain, which
may directly produce neuronal damage or promote
microglial inflammation [93,94].
Blood Brain Barrier (BBB) disruption
The BBB separates the brain from the circulatory system
and protects the central nervous system from potentially
harmful chemicals while regulating transport of essential
molecules and maintaining a stable environment [95,96].
Specialized endothelial cells that line brain capillaries
and transduce signals from the vascular system and
brain form its structure. Both the structure and function
of the BBB is dependent upon the complex interplay bet-
ween the different cell types (such as the endothelial
cells, astrocytes, and pericytes), and the extracellular
matrix of the brain and blood flow in the capillaries [97].
Three sites have been identified with a physical barrier
via tight junctions that include the brain endothelium
(forming the BBB), the arachnoid epithelium (forming
the middle layer of the meninges), and the choroid
plexus epithelium, which secretes CSF [91].
The BBB contains specialized endothelial cells that are
attached through tight junctions and adherence junctions,
which function to separate the CNS from the circulation
and restrict and prevent blood-borne molecules and per-
ipheral cells from entering the CNS [98]. Further, tight
junction proteins also provides the BBB with two func-
tionally distinct sides: the luminal side facing the circula-
tion and the abluminal side facing the CNS parenchyma,
which are highly sensitive to major cytokines produced
during such a response, including TNF-α, IL1-β, and IL6
[99]. Inflammatory cytokines of the TH17 and TH9 fam-
ilies (vide infra) may contribute in opening selected
“gates” through the BBB (Barkhordarian et al., Bioinforma-
tion, in press).
Experimental studies of human cultured embryonic
cells have demonstrated that virus-like particles (VLPs)
consisting of the Ebola virus matrix protein VP40 and
GP1,2 activated endothelial cells and disrupted barrier
function. This was further enhanced by TNF-α, which is
known to induce a long-lasting decrease in endothelial
cell barrier function and is hypothesized to play a key
role in Ebola virus pathogenesis [100].Other viruses, including the Human Immunodeficiency
Virus (HIV), produce viral proteins such as gp120, Tat,
and Nef released from infected cells, which lead to in-
creased expression of adhesion molecules such as inter-
cellular adhesion molecule (ICAM)-1 and endothelial
adhesion molecule [101]. These molecules facilitate the
transport of HIV within these infected macrophages by
promoting their ability to bind and migrate across the
BBB, although cell-free virions are also thought to be able
to cross the BBB due to changes in tight-junction forma-
tion [102,103].
Neurological syndromes
In 1967, cases of hemorrhagic fever occurred in Marburg.
The Marburg virus (MBGV) and EBOV, as noted above,
are both members of the family Filoviridae, and are very
similar in terms of morphology, genome organization, and
protein composition [104]. The pathology of Marburg dis-
ease was investigated from gathering tissues from brain,
spleen and liver from those infected and have been used
to make inferences about the pathology of Ebola virus.
Brain tissue derived from those infected with the Marburg
virus were noted for brain swelling, increases in vas-
cular permeability, associated reduced effective circulating
blood volume, and interstitial edema in the brain. The
pathologic alterations found in Ebola virus infection ap-
pear to share similar features to those found in Marburg
virus infection, though an absence of comprehensive com-
parative studies remain.
EBOV has been found to infect the meninges. Most
viral infections that involve the meninges can manifest
into progressive neurologic disorders. Clinical findings
reflect disease progression and the specific areas of CNS
involvement, which is determined by viral tropism [105].
For example, polioviruses preferentially infect motor
neurons, mumps infects epithelial cells of the choroid
plexus [106]; however, the tropism of filoviruses remain
unclear [107].
Encephalitis due to infection, post-infections encephalo-
myelitis (which may occur after measles or Nipah virus
encephalitis) and conditions such as post-poliomyelitis
syndrome, which some believe is a persistent manifes-
tation of poliovirus infection, are examples of neurological
syndromes that can occur with Ebola virus invasion.
Symptoms that signal encephalitis due to infection of
the meninges include sudden fever, headache, vomiting,
heightened sensitivity to light, stiff neck and back, confu-
sion and impaired judgment, drowsiness, weak muscles, a
clumsy and unsteady gait, and irritability. Even if the blood
brain barrier is not impaired, neuroinflammatory media-
tors crossing the BBB may result in neurotoxic effects due
to the accumulation of free radicals from the brain’s cyto-
toxic response [108]. Symptoms that require emergency
treatment include loss of consciousness, seizures, muscle
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from Cryptococcus usually develops among patients with
compromised immune systems (e.g., elderly, AIDS pa-
tients). CT or MRI is usually recommended first, before
the lumbar puncture [109]. Encephalitis and meningitis
can cause cerebral edema, and cerebral edema among
those infected with Ebola virus has been reported. Cere-
bral edema is a dangerous condition where the brain’s
water content rises, causing the pressure to rise in the
skull. Swelling can disrupt oxygen supply as the blood ves-
sels become squeezed. Cerebral edema is a medical emer-
gency that can even lead to death as brain cells become
damaged and die. Global cerebral edema is a powerful and
consistent predictor of cognitive dysfunction [110]. How-
ever, determining the long-term cognitive consequences
of these cases are rare, as they are often associated with
high mortality rates.
In brief, while the research on the direct effects of
EBOV on CNS is limited, we can only draw from know-
ledge about viral entry, viral propagation, and multiple
organ failure about the potentially profound effects on
the central nervous system. Survivors are at increased
risk for cognitive impairments. As with most neuro-
logical conditions, prognosis for cognitive outcomes will
be based upon the timing between infection, diagnosis,
and treatment.
Immunopathology
Infection with EBOV leads to aggressive and highly lethal
hemorrhagic fever in humans. Its virulence is associated
with a variety of processes and events that engage, and sub-
sequently blunt cellular immune surveillance. Initial im-
mune responses include a rapid rise in pro-inflammatory
cytokines (e.g., IL6, TNF-α), which trigger a relatively
short-lived initial burst of fever and inflammation often
disregarded by the patient, as well as cellular immune mi-
gration factors (e.g., IL8). Soon into the immune sur-
veillance response, which commences immediately after
infection, a slower process on cellular pathology ensues,
which includes myeloid cell and endothelial cell infection
and cytopathology. Consequential to this second phase are
both a sharp rise in fever, and loss in vascular integrity,
which leads to increased permeability of blood vessels with
transudates increasingly rich in micronutrients, red blood
cells and eventually white blood cells. Deficiencies in spe-
cific and nonspecific immune-driven antiviral responses re-
sult in unrestricted EBOV replication and dissemination in
the host, which together lead unavoidably - unless prompt
intervention is engaged to prevent EBOV binding to target
cells or block its replication within infected macrophages
and dendritic cells, and/or to counter the physiological col-
lapse due to dehydration secondary to heavy bleeding and
violent diarrhea - to death within 14 days following the
appearance of EVD symptoms.In brief, EBOV actively subverts both innate and adap-
tive immune responses, and triggers harmful inflam-
matory responses that inflict direct tissue damage. The
organism is ultimately overwhelmed by a combination of
inflammatory factors and virus-induced cell damage, par-
ticularly in the vasculature, often leading to death from
liver and kidney failure, complicated by septic shock [111].
The filoviridae family of viruses, including EBOV, causes
severe impairment of innate and adaptive antiviral cellular
immune responses, in part as a result of virally encoded
immune antagonists, which render the host incapable of
mounting effective innate or adaptive immune responses.
Type I interferon, which include IFN-α, IFN-β, IFN-κ,
IFN-δ, IFN-ε, IFN-τ, IFN-ω, IFN-γ and IFN-ζ, are im-
paired by EBOV. Of these IFN-α and IFN-β are secreted
by lymphoid and myeloid cells, and play an important role
the anti-viral cellular immune response. Certain filoviral-
encoded components target IFN-α and IFN-β responses,
and blunt the immune-mediated suppression of viral rep-
lication, thus favoring and Ebola pathogenesis. Case in
point, EBOV VP35 facilitates immune evasion of EBOV
by inhibiting the phosphorylation of interferon regulatory
factor 3 & 7 (IRF3/7) by TANK-binding kinase 1 (TBK1)
and IkappaB kinase epsilon (IKKε) (TBK1/IKKε) kinase
activity jointly as it acts to sequester the EBOV viral RNA
from detection by retinoic acid inducible gene-I (RIGI)-
like receptors. As such, EBOV (and MRGV) VP35 acts as
an interferon inhibitory domain (IID). Moreover, EBOV
VP24 inhibits nuclear translocation of activated STAT1
by karyopherin-α, thus rendering cells refractory to
IFNs [112,113].
EBOV-like particles (eVLP), composed of the EBOV
glycoprotein and matrix viral protein (VP)-40 with a lipid
membrane, are a highly efficacious method of immu-
nization against EBOV infection. The exact requirements
for immunity against EBOV infection are poorly defined
at this time. Vaccination of BALB/c or C57BL/6 mice with
eVLPs in conjunction with QS-21 adjuvant resulted in
mixed IgG subclass responses, a Th1-like memory cyto-
kine response, and protection from lethal EBOV challenge.
Further, this vaccination schedule led to the generation of
both CD4+ and CD8+ IFN-γ producing T cells recogni-
zing specific peptides within glycoprotein and VP40. The
transfer of both serum and splenocytes, but not serum or
splenocytes alone, from eVLP-vaccinated mice conferred
protection against lethal EBOV infection in these studies.
B cells were required for eVLP-mediated immunity to
EBOV because B cell-deficient mice vaccinated with
eVLPs were not protected from lethal EBOV challenge.
CD8+, but not CD4+, T cells are absolutely required for
eVLP-mediated protection against EBOV infection. Fur-
ther, eVLP-induced protective mechanisms appear to be
perforin-independent, but IFN-γ-dependent. Taken to-
gether, both EBOV-specific humoral and cytotoxic CD8 +
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filoviruses following eVLP vaccination [114].
In brief, the first telling symptoms of incipient EVD
include high fever and bleeding from the orifices. As
dendritic cells and macrophages succumb to EBOV in-
fection, the cellular immune surveillance mechanism is
progressively impaired, and virus titter rises, as does
EBOV-caused cyto-and physiopathology. Immune eva-
sion events of EBOV include:
 inhibition of innate immunity that precipitates
down-regulation of type I interferons, as well as
IFN-γ,
 EBOV epitope masking,
 subversion of the adaptive humoral immunity, and
 secretion of truncated forms of the viral
glycoprotein (e.g., GP, ssGP) [115].
It is possible and even probable that EBOV-infected
dendritic cells and macrophages soon invade specific
organs, and establish themselves as EBOV-infected resi-
dent myeloid cells. Case in point, renal myeloid cells rep-
resent a constitutive, extensive and contiguous network of
local immunity cells that provide sentinel immune surveil-
lance. They contribute to induce and regulate inflamma-
tory responses to protect the kidney from infection. They
are a perfect example of local immunity, as similar sen-
tinel myeloid cells are found in every organ to play key
factors in the initiation and propagation of renal disease,
as well as essential contributors to subsequent tissue
regeneration, regardless of etiological and pathogenesis
mechanisms [116].
Indeed, dendritic cells and macrophages, in part be-
cause of their high degree of motility, play a critical role
in the cross-talk between systemic and local immunity,
including between the central nervous system and mu-
cosal immunity – that aspect of local immunity is most
likely to be severely affected during EBOV infection.
HIV is another RNA virus that infects myeloid cells:
HIV+ dimCD4 +macrophages leave the systemic im-
munity environment, to infiltrate in the local immunity
of the intestinal mucosa, in so doing, contribute to pro-
mote local inflammation and injury to the intestinal lin-
ing, contributing to loss of the resident intestinal flora
and heavy diarrhea [117]. More generally speaking, HIV
can escape from systemic immunity assessments simply
by becoming hidden in macrophages and dendritic cells
that transmigrate from the systemic compartment to or-
gans and lymph nodes, such that lymphadenopathy is a
clinically relevant sign and important guiding tools for de-
tecting hidden HIV in asymptomatic individuals [118,119].
Evidently, we do not know if this is the case in EBOV
infection as well because the pathology of EVD is so ful-
minant and lethal. However, as the number of EBOV+survivors will continue to increase, it will behoove us to
be more prudent and less euphoric in our statement that
such and such a patient is “cured” from Ebola: rather, we
ought to consider the likelihood that EBOV, like HIV,
could become hidden in the micro-environment of local
immunity, thus becoming undetectable as virions or
viral particles in the systemic circulation. This even-
tuality should be particularly apparent when “cured”
patients retain high titers of circulating anti-EBOV anti-
bodies, or certain symptomatologies (e.g., severe head-
aches, confusion, fever).
EBOV causes highly lethal hemorrhagic fever that leads
to death in up to 90% of infected humans, depending on
the Ebola virus species. Like many other infections, EBOV
induces massive lymphocyte apoptosis, which is thought
to prevent the development of a functional adaptive im-
mune response. In a murine experimental model of EBOV
infection, data described an increase in expression of the
T cell activation-migration-maturation marker CD44 in
CD4+ and CD8+ T cells. CD44 is a cell-surface glyco-
protein involved in cell–cell interactions, cell adhesion
and migration. The percent and absolute numbers of the
CD4 +CD44+ and CD8 + CD44+ subpopulation sharply
increase in the later phase of EBOV infection, preceding
death. In many instances, this event is accompanied by a
dramatic rebound of lymphocyte numbers in the blood,
which however appear to be apoptotic lymphocytes, sug-
gesting that local (i.e., spleen) and systemic cellular
immunity might be characterized by considerable un-
productive lymphocyte activation, and consequential pro-
grammed cell death in the later stages of EBOV infection.
Data have indeed shown that, despite significant lympho-
cyte apoptosis, a functional and specific, albeit insufficient,
adaptive immune response is made in lethal EBOV infec-
tion and could be protective upon transfer to naive infected
recipients. These findings may spark new immune-based
therapeutic strategies to control EBOV and EVD [120].
EBOV infection induces massive lymphoid and mye-
loid apoptosis. Data have established that EBOV-induced
lymphocyte apoptosis in vivo occurs via both the death
receptor (extrinsic) and mitochondrial (intrinsic) path-
ways. Inhibiting lymphocyte apoptosis during EBOV
infection fails to improve animal survival rates [121], in-
dicating that the immunopathogenesis induced by EBOV
occurs upstream from T cell activation. Clearly, one
must surmise from these findings, taken together, that
EBOV infection of antigen-presenting cells, such as mac-
rophages and dendritic cells, must alter the plasma
membrane structure of the host cell, such that the T cell,
while recognizing the non-self/self complex, fails to find
a functional CD80 (B7.1) and CD86 (B7.2) receptor on
the membrane of the EBOV-infected antigen presenting
cell for its CD28 co-activating membrane moiety. Alter-
natively, the T cell inducible costimulator (ICOS) might
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EBOV-infected macrophages and dendritic cells. The hy-
pothetical model we propose here is grounded on our
current understanding that costimulatory signals, such
as CD28 and ICOS are critical for the establishment and
maintenance of systemic and local cellular and humoral
immune surveillance, and rests on previous observations
in a related model that demonstrated that the impair-
ment in the B7 family-ligand costimulatory pathways
may promote tumor immune evasion by providing a
negative regulatory signal equivalent to T cell apoptotic
cell death [122]. Indeed, this paradigm has led to the de-
velopment of a variety of immunotherapies targeting
costimulation pathways [123-125]. It follows that future
clinical trials in EBOV+ patients may require testing im-
munotherapeutic interventions such as these as prevent-
ive or palliative means of blunting EVD.
Clinical interventions
Currently the diagnosis of Ebola is difficult [61,126,127],
and there are no specific vaccines or medicines (such as
antiviral drug) that have been proven to be effective
against Ebola. Symptoms of Ebola are treated as they ap-
pear. The following basic interventions, when used early,
can significantly improve the chances of survival:
 Providing intravenous fluids and balancing
electrolytes
 Maintaining oxygen status and blood pressure
 Treating other infections if they occur
Timely treatment of EVD is important but challenging
since the disease is difficult to diagnose clinically in the
early stages of infection. Because early symptoms such
as headache and fever are not specific to ebolaviruses,
cases of Ebola may be initially misdiagnosed, as noted
above [128].
Vaccines
We discussed elsewhere the main difficulties in developing
vaccines for HIV [129]. Similar concerns arise for related
RNA viruses, including the filoviruses, and EBOV in par-
ticular. As for anti-HIV vaccines [129], the most promis-
ing anti-EBOV vaccine candidates are DNA vaccines
raised against the EBOV cDNA, vaccines derived from
adenovirus-EBOV conjugates, or vaccines directed against
certain EBOV components, such as VLPs. Using mRNA
extracted from bone marrow of Ebola survivors, human
monoclonal antibodies against Ebola virus surface protein
have been experimentally produced and now raise the
hope for the development of a safe vaccine [130]. How-
ever, as of November 2014, no vaccine was approved for
clinical use in humans, or even developed, tested for
toxicity, and distributed for that initial purpose.The complexity in developing a EBOV-specific vaccine
is in part the reason why no licensed vaccine is available
yet. It is also the case that prior outbreaks, considering
their size and relative containment, failed to evoke the re-
sponse of the national and international scientific commu-
nity in pursuit of an anti-EBOV vaccine [131,132]. Even in
the course of the present epidemic, the call for the deve-
lopment of an effective vaccine protective against Ebola
was relatively subdued until EBOV+ patients were identi-
fied on European and US soil. Now, Ebola vaccines are
undergoing active investigation, particularly in light of a
more complete understanding of the genomic and prote-
omic properties of EBOV [133].
By all accounts, a vaccine is necessary to halt the
present Ebola epidemic. The two most advanced candi-
dates have recently entered safety and efficacy trials.
Should they prove non-toxic and efficient in triggering
the needed immune response, then WHO might re-
commend bypass of the usual careful screening and tes-
ting process, and immediate utilization in what would
amount to phase III efficacy tests in Liberia, Guinea, and
Sierra Leone, and possibly in Western Europe and the US
as well. Case in point, Canada’s National Microbiology
Laboratory developed an experimental vaccine that com-
bines fragments of Ebola virus with the non-fatal adeno-
virus. The vaccine appears promising, and testing in the
US (Walter Reed Army Institute of Research) has begun,
and will follow presently with testing in Western Europe
and Africa. However, the safety and effectiveness of the
Canadian vaccine in humans remains unknown at this
time. Similarly, simultaneous phase I trials of an experi-
mental vaccine (NIAID/GSK), based on a modified chim-
panzee adenovirus conjugated to portions of Zaire and
Sudan EBOV, and developed jointly by GlaxoSmithKline
and NIH, commenced in September 2014. If this phase is
completed successfully, then a stockpile of 10,000 doses of
the vaccine could be fast tracked for use in West Africa
and world-wide, perhaps as early as early 2015, although
full validation studies will not be completed by then.
GlaxoSmithKline website reported in mid-October
that “…“development of the vaccine candidate is progres-
sing at an unprecedented rate, with first phase 1 safety
trials with the vaccine candidate underway in the USA,
UK and Mali, and further trials due to start in the com-
ing weeks…”. As an inevitable sequela of this fast-track
process however, difficult bioethics questions are emer-
ging in the rationale that would determine who would
be tested with these vaccines, vs. others who would be
left to face a quasi certain lethal fate [134].
Pharmacological interventions
Without an approved vaccine or treatments, Ebola out-
break management has been limited to palliative care
and barrier methods to prevent transmission. These
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epidemic grows exponentially. Certain drugs have been
approved for use in Ebola patients, and characteristically
inhibit filovirus cell entry, such as amiodarone, drone-
darone and verapamil [135].
Alternative pharmaceutical interventions, such as the
combination of monoclonal antibodies optimized from
two previous antibody cocktails (ZMapp, produced by
Novartis, Mapp Biopharmaceutical, and others), appears
to rescue 100% of rhesus macaques when treatment is
initiated up to 5 days post-challenge. High fever, viremia
and abnormalities in blood count and blood chemistry
are relieved following ZMapp intervention. Advanced
disease, as indicated by elevated liver enzymes, and
ZMapp reverses mucosal hemorrhages. In brief, ZMapp
exceeds the efficacy of any other therapeutics described
so far, such as RNAi-based TKM-Ebola, or antisense
based AVI-7537) [136-138].
ZMapp outcomes were so promising to warrant
further development of this cocktail for clinical use.
Indeed, it was administered to the two US medical
workers Dr. Kent Brantly and Nancy Writebol, who had
contracted EVD in Liberia, were transported to US hos-
pital, and, following ZMapp treatment, recovered from
Ebola. ZMapp is certainly not the “miracle drug”, how-
ever, as the case of the Spanish priest who got infected
with EBOV in Liberia, and eventually died of Ebola in
Madrid a few days into his treatment regimen with
ZMapp demonstrates. Teresa Romero, the nurse who
treated him, contracted the disease and was the first case
of Ebola contracted and diagnosed outside of the African
continent, as discussed above.
Toward novel interventions
Cellular immunity
Case reports of acutely ill patients with EVD showing
improvement with the transfusion of plasma from EVD
survivors may seem at odds with the idiotypic antibody
network model of immunoglobulin regulation, first ad-
vanced four decades ago [139]. However, in the case of
EBOV, which is know to disrupt cellular immunity up-
stream of T cell activation and differentiation into lym-
phocytes capable of either the TH1 or TH2 pattern of
cytokines, it appears plausible that replenishment of im-
munoglobulin may actually be protective, rather than
nefarious to the humoral immune response, at least
during a certain window in time of immunopathology.
The microenvironment of organisms is greatly depen-
dent on the intricate, fluid relationships that exist between
the different subpopulations of T CD3+ cells, and the
pattern of cytokines they produce. Murine immunology
has revealed two principal clones of T cells characterized
by their secreted cytokines, Thelper1 (Th1) and Th2.
Human immunology studies uncovered similar patterns ofcytokines, which however could not be cloned as in the
murine system for obvious reasons. Therefore, and to re-
call the murine model, these patterns are referred to as
TH1 and TH2 T cell subpopulations. Whereas the human
TH1 cytokines (e.g., IL2, INF-γ, IL12) predominantly favor
T cell activation, proliferation and maturation for cellular
immunity toward parasites, virally infected cells and
tumor cells, the TH2 cytokine profile (e.g., IL4, IL5, IL10)
favors the activation, proliferation and maturation of B
cells and enhance humoral immunity and the production
of antibodies. A third population was soon characterized
both in the murine and in the human systems, which
down regulated T cells responses, and tended to blunt
cellular immunity: this regulatory T cell subpopulation
(Tregs) was characterized by tri-immunofluorescence flow
cytometry to express either CD4 or CD8, to be mostly
constituted of activated cells expressing the α chain of the
IL2 receptor, CD25, and the characteristic key signature of
Tregs, FoxP3. Further characterization revealed that, de-
pending upon the microenvironment, TH1 populations
might engender a TH17 subpopulation, whose cytokine
profile (e.g., IL17-A, IL-17 F, TNF-α, IL22, IL23, and IL9
in low concentrations) lends to a state of sustained T cell-
driven inflammation seen in in autoimmune diseases and
allergic reaction, or TH2 cells may generate TH9 subpop-
ulations characterized by elevated levels of IL9 and IL10.
Recent data indicate that Tregs play a critical role in
directing and regulating the dynamic plasticity of the
balance of TH1/TH2, and of the intimately related TH17/
TH9 subpopulations [140-144].
TH1/TH2 and TH17/TH9 relationship is pivotal in
maintaining the efficiency of cellular immune sur-
veillance. Should the hypothesis that EBOV impairs the
host’s cellular immunity by altering the Tregs-mediated
regulation of TH1, TH2, TH17 and TH9 plasticity be
proven true, then novel immunotherapies could be de-
signed and tested on EVOV+ patients directed speci-
fically at restoring the physiological homeostasis in TH1,
TH2, TH17 and TH9 cytokines.
Case in point, IL23 is important for the expansion of
TH17 cells and thus the production of IL17-A and IL9.
However, IL23 is not necessary for the initial differenti-
ation of TH17 cells but it maintains and stabilizes the
TH17 lineage [143], which itself is the principal driver
for the maintenance of TH17-mediated T cell-induced
and -sustained inflammation. By promoting Tregs, the
expression of IL23-receptor is abrogated, which leads to
the inhibition of IL23 production, and consequentially
TH17-driven events are blunted, As a result, a plausible
increase in TH9 cells should occur due to the strive for
balance of TH17 and TH9 cells in the immune system.
It is also the case that IL6 and low concentration of in-
duces IL-23 receptor expression and high concentration
of TGF-β inhibits IL23 receptor and mediates a dynamic
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transcription factor [142-144].
In brief, cellular immune surveillance is a dynamic and
fluid system that is driven by a finely balanced and deli-
cately regulated equilibrium of cytokines. The microen-
vironment of the organism, which is profoundly altered in
the case of EBOV infection and the consequential physio-
logical breakdown in EVD, dictates and regulates whether
or not there is a predominant TH1 and TH17, or TH2
and TH9 pattern of cytokines. It follows that novel immu-
notherapeutic modes of combating EBOV immunopatho-
logy may simply lie in rectifying the cytokine relationship
and the fluidity of the T cell subpopulations that are dri-
ving these cytokine patterns.
Reiterating the concepts made above, the observation
that seven of eight patients with Ebola survived after re-
ceiving a transfusion of plasma donated by individuals
who had previously survived the infection is coherent
with both our current understanding of cellular immun-
ity, and of the immunopathology mediated by EBOV. In
brief, intravenous antibodies appear to be protective, and
therefore, WHO has approved the use of convalescent
serum and plasma to treat patients with Ebola.
EBOV-infected macrophages and dendritic cells pro-
duce pro-inflammatory cytokines, chemokines and tissue
factor, attracting additional target cells and inducing
vasodilatation, increased vascular permeability and dis-
seminated intravascular coagulation. However, they ap-
pear incapable of restricting viral replication, in part
because of impaired interferon responses (vide supra),
but also because of other cytopathic mechanisms yet un-
clear. Consequently, EBOV spreads throughout the body
via these cell populations, and causes multifocal sites of
necrosis and septic shock-like syndrome. Massive apop-
tosis of natural killer and T cells accompanies these
events, as noted above, and this further impairs immun-
ity [127,145,146]. These findings suggest that the virus
causes profound alterations in macrophage biology, and
that perhaps modifying host responses via correcting
EBOV-caused macrophage defects could become an ef-
fective alternative therapeutic strategy in the treatment
of Ebola.
Macrophages are myeloid derivatives that mature from
monocytes and that process foreign materials by phago-
cytosis, a process that has evolved in vertebrate im-
munology to recognize pathogens and damaged tissues
through Toll receptors, as well as pathogen-associated
molecular patterns (PAMP) and damage-associated mo-
lecular patterns (DAMP) [146-155]. In general terms,
macrophages either turn on their killing program and
“fight” against an invading pathogen and defend against
subtle variations of self and to develop and engage spe-
cific T cell-mediated immune responses, or they engage
in a “fix” repair and remodeling program. Macrophageseither elicit responses that include nitric oxide and oxy-
gen radical production, which have been described as a
M1-type macrophage response, or production of factors
that promote proliferation, angiogenesis, and matrix
deposition, which together represent a M2-macrophage
response [147,149,152,156,157].
Macrophage-like cells have varied tissue distributions,
and have different names depending on their anatomical
sites. In the central nervous system, macrophages are
called microglial cells whereas hepatic macrophages are
referred to as Kuppfer cells, in the lungs they are re-
cognized as alveolar macrophages whereas skin macro-
phages are the Langerhans cells [147,152]. Depending on
their histologic and microenvironment, macrophages
have distinct functions, so that Langerhans cells, for ex-
ample, are most often engaged in encountering damage
signals due to wounds and act predominantly in an M1-
type response, whereas alveolar macrophages, for instance,
predominantly engulf inhaled materials and work predo-
minantly in an M2-fix modality.
M1 and M2 are oversimplified descriptions of the com-
plex processes brought about by macrophages in their
function as director of the innate immunity orchestra; but,
the model provides a useful dichotomous functional clas-
sification that segregates the macrophage toxicity from its
repairing activity at the cellular and histological level. In
brief, M1 and M2 refer to two different, actually opposing
and balancing states and activities of macrophages: in the
M1 stage, cells predominantly produce cytotoxic levels of
nitric oxide, whereas cells at the M2 stage largely secrete
cell- and tissue levels of ornithine [157,158].
Macrophages actively metabolize arginine either to
nitric oxide and citrulline via the inducible nitric oxide
synthase pathway (iNOS) (M1 physio-toxic profile), or
to ornithine and urea via the arginase pathway (M2
physio-repairing profile). Nitric oxide is the primary ef-
fector molecule used by macrophages to kill pathogens
or eliminate host cells [159-163]. By contrast, ornithine
is a precursor of polyamines, which are required for
DNA replication [164,165], as well as of L-proline, a
major component of collagen that is required for tissue
repair and serves as a matrix promoting cell replication
[166,167]. The M1 macrophage pattern influences TH1
cytokines, including IL-12, which drive T-cell sustained
inflammation (i.e., TH17), activation, proliferation and
maturation; by contrast, macrophages in the M2 state
tends to favor TH2 patterns of cytokines, which support
humoral immunity, including B cell proliferation, matu-
ration and secretion of antibodies [148,152,153].
One among the most powerful stimuli for iNOS, and
therefore for inducing M1 macrophages is IFN-γ. Nitric
oxide and citrulline can be generated during both innate
and adaptive immune responses since T lymphocytes
and natural killer cells, upon activation, produce large
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TH1 cytokine produced by dendritic cells and macro-
phages, stimulates IFN-γ and thus contributes to driving
forward M1 macrophages [163,165,171,172]. By contrast,
TGF-β1 stimulates the arginase pathway, and is potent
inhibitor of iNOS, such that the constitutive production
of TGF-β1 and nitric oxide by macrophages is inversely
correlated: TGF-β1 serves as an autocrine regulator for
iNOS, an endogenous switch, as it were, that signifi-
cantly contributes to determining a M1 or an M2 stage
[157,163,169,173-182]. IL4 induces TH2 responses, while
suppressing TH1 patterns of cytokines, and together
with IL13 contributes to inhibiting the production of ni-
tric oxide, inducing arginase and favoring the transition
to the M2 state of macrophage function [154,183,184].
In a classic pattern of cellular immune surveillance,
pathogens and cyto-histological damage, including cancer
and virally-infected cells, are detected through PAMP and
DAMP within hours; shortly thereafter, a set of signals are
produced by resident macrophages, which are dedicated
to act as M1 macrophages within a day of the insult.
Simultaneously, levels of IFN-γ produced by immune im-
munity cells rise, which further elevate the M1 response
[149-151,156,171,185-190].
As the pathogen invades lymph nodes, the lymph
nodes antigen-presenting cells (i.e., dendritic cells) pro-
voke, by their presenting the antigen, the clonal proli-
feration of antigen-specific T cells [191]. During a M1
macrophage response, IL12 and IL23 are secreted, which
signal T cells to elicit a TH1 response, including high
levels of IFN-γ. The ongoing M1 response is therefore
sustained, and TH17 activation ensues further ampli-
fying the M1 cytotoxic and histopathologic response
[191]. By contrast, when the pathogen is contained by
the M1 pattern of response, then M2 state macrophages
engender a pattern of cytokine that is associated TH2
pattern of cytokines. This includes IL10 that shuts down
the TH1 cytokine response, as well as IL4 and IL13 that
promote antibody production for the removal of the
pathogen, and TGF-β-1 that further induces arginase for
cell and tissue rebuilding and repair. Therefore, to a
INF-γ/TGB-β-1 balance and a TH1/TH2 balance seem
to correspond a M1/M2 balance and a tissue destruction
by virtue of excessive nitric oxide and related cytotoxic
compounds vs. a tissue regeneration modality resulting
from arginase-mediated production of polyamines for
DNA repair and L-proline and ornithine for cell and tis-
sue repair [191-193].
If the hypothesis can be brought forward that EBOV
selectively alters the M1/M2 balance because it is tropic
to macrophages and dendritic cells – a hypothesis that
could be tested relatively simply by in vitro manipula-
tions followed by tri- or tetra-immunofluorescence flow
cytometry – then, the inference can be brought forwardthat EBOV may contribute to drive and sustain an M1 state
simply because of the chronic depletion of ebolavirus-
infected macrophages and the need to generate new mye-
loid derivatives to combat the pathogen. Consequently, a
state of super-induced iNOS could ensue – a hypothesis
equally testable with biopsy specimens from Ebola
patients – and the associated profound cellular and phy-
siological toxicity, which could contribute to the system
collapse that manifests in the advanced stages of EVD.
Novel immune-based interventions for Ebola patients
might therefore involve modulating the M1/M2 balance
by attenuating M1 responses and favoring an M2 macro-
phage state.
Indeed, macrophage-directed interventions include 2
pharmacotherapeutic drugs directed at impairing macro-
phage survival [194,195], although it is not clear if it may
specifically target M1 or M2. Research shows, at least in
the context of central nervous system microglia and in-
vading macrophages, that NF- κB p50 is a key redox-
signaling mechanism regulating the M1/M2 balance,
which preferentially drives M1 responses [196,197].
Microparticles and micronutrients
The deregulation of coagulation cascade due to EBOV
hemorrhagic fever is a syndrome that causes disseminated
intravascular coagulation, which leads to micro-thrombi
and related fibrin deposition in the microvasculature.
Multiple organ failure ensues, as was outlined above. At
the molecular level, the overexpression of the extrinsic tis-
sue factor (TF) trans-membrane glycoprotein is respon-
sible for fibrin deposition. That TF is expressed, not by
endothelial cells, but by myeloid cells is indicative of puta-
tive TF alterations in EVD since, as noted, EBOV infects
monocytes and macrophages. Data obtained in ex-
perimentally EBOV-infected macaques show altered TF
expression on microparticles, small vesicles (0.2–1 μm)
derived from cell plasma membranes and acting as inter-
mediate messengers, probably of myeloid cell origin.
Microparticle TF, detected by days 4 and 5 post-infection,
were shown to have an important pro-coagulant role.
Taken together, these preliminary studies suggest that che-
motherapeutic strategies aimed at controlling overexpres-
sion of microparticle TF may prove to be an effective
intervention to counter EBOV-induced EVD hemorrhagic
fever [198].
Selenium is an essential micronutrient in human
homeostatic physiology. Selenium acts as an essential
component of the unusual amino acids, seleno-cysteine
and seleno-methionine. In states of selenium deficiency,
cells cannot synthesize seleno-proteins, which act not only
in selenium transport, but also as essential auto-oxidants
to maintain cell health and to prevent cytopathic manifes-
tations. Seleno-proteins also maintain physiologic balance
through their anti-inflammatory properties. Selenium is
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ment [199]. Seleno-cysteine proteins contain selenium in
their active site in the form of their 21st amino acid
seleno-cysteine, which is encoded by an in-frame UGA
stop codon [200]. Several UGA codons lie in Ebola
genome and some seleno-cysteine insertion sequences
(SECIS), in particular stem-loop structures, were predicted
in mRNAs analyses. It is possible and even probable that
EBOV UGA codons may encode seleno-cysteine, thereby
depleting the selenium available to the host cell, impairing
eukaryotic seleno-protein translation, and prompting lipid
peroxidation and consequential cellular damage. Second-
arily, selenium depletion may lead to both enhanced
thrombosis and decreased immune surveillance processes,
acting in concert to worsen hemorrhagic symptoms [201].
It follows that novel nutritional paradigms aimed at
replenishing selenium might be desirable for maximum
protection against, and recovery from EVD.
MicroRNA
MicroRNA is a small non-coding RNA molecule, which
is usually smaller than 20–22, and which functions to
silence RNA post-transcriptional regulation of gene
expression generally by forming base-pairing with com-
plementary sequences within mRNA molecules. Animal
miRNAs are usually complementary to a site in the
3’-UTR, and function in gene regulation principally by
inhibiting protein translation of the target mRNA, and
occasionally by inducing modification of histone and
non-histone protein, and DNA methylation of promoter
sites, which affects the expression of target genes. It is
current dogma that regulation of miRNA preserves nor-
mal functioning of eukaryotic cells, whereas deregulation
of miRNA may be associated with disease.
Case in point, two putative viral microRNA precursors
(EBOV-pre-miR-1 and EBOV-pre-miR-2) and three
putative mature microRNAs (EBOV-miR-1-5p, EBOV-
miR-1-3p and EBOV-miR-2-3p) derived from the EBOV
genome have been identified [202]. Data have also
shown that certain proteins that are down-regulated in
EBOV infection, such as tissue factor pathway inhibitor,
dystroglycan1, caspase 8 FADD-like apoptosis regulator.
Inhibition of the mi-RNAs hsa-miR-1246, hsa-miR-320a
and hsa-miR-196b-5p can actually rescue the cell via-
bility that was induced by EBOV glycoprotein [203].
Taken together these findings suggest a novel molecular
basis for EBOV pathogenesis, and a new molecular
therapeutic and preventive strategy for EBOV+ patients.
Translational effectiveness
Recent developments in health care have witnessed the
evolution of the original conceptualization of translational
research into translational science in medicine, dentistry
and nursing. Translational research, as originally defined byNIH, requires that sample biopsies obtained from
individual patients be analyzed and characterized in the
laboratory, and that the outcome of these studies be inte-
grated in the clinical decision-making for treatment. Trans-
lational effectiveness, as later defined by AHRQ, defends
that another major component of clinical decision-making
must rest on obtaining, disseminating and utilizing the best
available evidence in specific clinical settings [27]. Disse-
mination must be directed in various forms and formats to
all of the stakeholders involved in the patient’s well-being -
from the patients themselves, to the caregivers, the health-
care team, and the patients’ friends and acquaintances.
Stakeholders play a critical role in the dissemination
process, be it person-to-person or via tele-medicine pro-
cesses, in caring for patients with EBOV infection.
Stakeholders in translational effectiveness
Stakeholders are important partners in the clinical
decision-making process, particularly in the context of
patient-centered healthcare homes and neighborhoods for
optimizing patient-targeted interventions [27]. Stakeholders
can include biologists, clinicians/clinical researchers, epide-
miologists, health services researchers, patients, family
members, caregivers, patient advocates, social workers, in-
surance carriers, and legal advisers, all striving to ensure
multidimensional and multidisciplinary contributions to
the multiplicity of patient-target endeavors in evidence-
based, patient-centered and effectiveness-focused clinical
decision-making [27]. Stakeholders contribute their skills
and knowledge to synergistically share the responsibility
of patient-targeted care. Active stakeholder engagement is
critical to the success of patient-centered, effectiveness-
focused and evidence-based intervention. Stakeholders in
modern healthcare engage as:
 Primary stakeholders: those individuals ultimately
and directly affected, either positively or negatively,
by the healthcare outcomes (e.g., patients, the
immediate family members, or caregivers of patients
who cannot represent themselves).
 Key stakeholders: individuals who may or may not
be primary stakeholders, but have a significant
influence on the decision-making process
(e.g., relatives, friends or caregivers empowered
by a legal document or directive to make healthcare
decisions on behalf of the patient).
 Secondary stakeholders: individuals indirectly
affected by the outcomes, or indirectly involved in
the patient’s care process.
 Allied stakeholders: individuals who are involved in
the patient’s care, but are indirectly affected by the
healthcare outcome (e.g., medical, dental, nursing
and pharmacy staff, other hospital employees,
insurance agents, legal staff and lawyers).
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stakeholder engagement is rarely uniform: not all stake-
holders have the same roles and degrees of involvement in
the healthcare experience, and, as noted above, stakeholders
may have very different perceptions of their responsibilities
across diverse social and cultural environments. It follows
that timely concerted research must be directed at the
development and validation of novel analytical tools to
establish the nature, level (or quantity), and quality of
stakeholder participation in healthcare [27,204,205]. Case
in point, the current spread of the Ebola epidemic might
have been mitigated somewhat, or perhaps even impeded
if proper stakeholder engagement procedures had been
established and implemented.
Stakeholder engagement ought to be evaluated syste-
matically in a process designed to identify and cha-
racterize the principal constructs and sub-constructs
related to the stakeholders’ engagement in terms of their
expected and perceived roles, involvement and function
[204,205], including:
 stakeholders’ actions and position;
 ability and intent to influence implementation;
 motivation to participate; and
 capability to change and adapt as the care situation
evolves, and calls for adaptive management)
Stakeholder engagement will play an important role in
the psycho-emotional recovery of EBOV+ patients and
patients afflicted with EVD. Further studies must be
conducted to design a coherent set of contribution to-
ward the patient well-being, such as increased health
literacy through dissemination [206], psycho-emotional
comfort, economic and societal support, etc., to validate
stakeholders benefit [27,203-206].
Telemedicine & eHealth
Telemedicine is an innovative medical technology system
aimed at improving dissemination of the best available evi-
dence and evidence-based revisions of clinical practice
guideline, with the purpose of empowering clinicians, pa-
tients and all stakeholders toward clinically more sound
and more informed decision-making. Telemedicine signi-
fies connecting health care providers, patients and care-
givers with expertise that is at great geographical distances
(e.g., West Africa community Ebola treatment units with
NIH health care system in Bethesda, MD) via electronic
communication technologies. Telemedicine seeks to im-
prove evidence-based, patient-centered and effectiveness-
focused cutting edge medical intervention globally [27].
Implementation of telemedicine subsumes health infor-
mation technologies (tele-care, electronic health records
and digital medical chart, support systems, user-friendly
multi-languages web-based packages and social media forspecial-needs patients, assistive information technologies
[e.g. touchless keyboards and pointing devices to minimize
cross-contamination], personal mobile phone apps, etc.),
and as such can take several forms [207-209]:
 tele-care can provide health care and assistance to
people who are physically less able (i.e. elderly,
disabled), from patient’s own homes
 digital, paperless medical charts provide immediate
access to patients’ medical records for efficient
information exchange and consultation among
medical specialists;
 support for diagnosis and clinical decision-making
for treatment plan via computer based information
and communication systems;
 web-based media for social support of patients and
stakeholders.
 are helpful to patients by providing patients/
caregivers information through social media
accounts and web-based information.
Case in point, the Réseau en Afrique Francophone pour
la Télémédecine (RAFT) network, was originally devel-
oped and established to connect Western European health
care systems (e.g., France) to African communities (e.g.,
francophone Africa) in order to provide educational, cli-
nical, and public health activities. Starting in the early
2000’s, educational programs were delivered on a weekly
basis via video-lectures and digital communications and
sharing to patient data and medical information for virtual
continuing education and training, guided evidence-based
clinical decision-making, and joint epidemiological re-
search activities. The clinical and public health activities
included web-based sharing of expertise for the manage-
ment of infectious diseases and complex clinical cases,
and for the implementation of clinical information sys-
tems in African hospitals. In 2010, the RAFT model was
extended to the Altiplano in Bolivia and Nepal [209].
In brief, novel interventions involving the full uti-
lization of telemedicine will be beneficial during the
present Ebola pandemic primarily because it will con-
nect all medical personnel across the world, from the
Médecins sans Frontières in West African countries, to
infectious disease specialists in Europe an the US
through a seamless network of health care consultation,
and joint progress toward the treatment of EBOV+ pa-
tients and their cure from EVD. Telemedicine is the best
approach to bring much needed expertise to the most
remote villages and communities where Ebola is ram-
pant presently. Through telemedicine, hospital specia-
lized in the diagnosis and the treatment of this disease,
and state-of-the-art Ebola treatment units, such as in the
US St. Patrick Hospital, Emory University Hospital,
National Institutes of Health and Nebraska Medical
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care centers around the world for the purpose of sharing
of medical data, information, consultation, and eva-
luation. More generally, the field of telemedicine can
provide novel, timely and critical wireless, touchless and
contamination-free instruments and devices – such as
the devices recently introduced at certain airports in
Europe and the US to monitor the passenger’s body
temperature – whose measurements can be immediately
recorded and transmitted digitally and wirelessly to na-
tional and international databases for health care infor-
mation storage and exchange among hospitals, health
care centers, WHO, CDC, and treating specialists.
From a bioethics perspective, and based on the RAFT
experience, effective integration and optimum use of
eHealth in emerging economies, such as West African
countries presently assailed by the Ebola epidemic, must
be articulated in a complex and interactive model of
care. Novel interventions in telemedicine must coordin-
ate the contextual health acre resources and infrastruc-
ture, the culture and anthropological nature of societal
environment, the needs of stakeholders, and the funda-
mental understanding of the physiopathology, histopath-
ology, cytopathology and molecular pathology of EBOV
infection and the resulting EVD.
Conclusion
The first cases of the current West African epidemic of
Ebola virus disease, Ebola, were reported on the 22nd of
March 2014. Seven months later, there were over 10,000
cases and close to 5,000 deaths, with about 20% EVD
cases reported in health care workers, across several
countries beyond the African continent, including the
US and the European Union.
Signs and symptoms of Ebola usually begin suddenly
with an influenza-like stage characterized by fatigue, fever,
headaches, joint, muscle, and abdominal pain. Vomiting,
diarrhea and loss of appetite are also common. Symptoms
such as headache, encephalitis, meningitis, cerebral edema,
and seizures commonly indicate CNS involvement. Less
common symptoms include sore throat, chest pain, hic-
cups, shortness of breath and trouble swallowing. Skin
manifestations include a maculopapular rash in about 50%
of cases. The average time between contracting EBOV in-
fection and the start of symptoms (incubation period) is
eight to ten days, but it can vary between 2 and 21 days, or
longer in some patients. Early symptoms of EVD mimic
malaria, dengue fever or other tropical fevers, before the
disease progresses to the bleeding phase. Specialized Ebola
treatment units must be designated and established to pre-
vent EBOV infection, and to control the spread of the dis-
ease. Intensive care in the developed countries includes
maintaining blood volume and electrolytes homeostatic
balance, and treating any collateral bacterial infections.Dialysis is required for kidney failure, and extracorporeal
membrane oxygenation in the case of lung dysfunction.
These interventions, however, are neither directed specific-
ally to contain EBOV infection, nor available routinely in
developing countries in Africa. It is timely and critical to
rapidly increase Ebola treatment units, to expand their
reach through telemedicine and eHealth protocols, and to
develop and disseminate innovative treatment methods for
communities urgently in need of support and assistance.
Cross-species transmissions, or “when pathogens infec-
ting one species ‘jump’ to infect another species,” ([210],
p. 117), are key to understanding global health in Africa’s
forests and beyond. Most human EIDs result from those
transmitted naturally between animals and humans
through “complex, dynamic, ongoing interactions between
pathogens, people, other mammals, and forest ecologies”
([210], p. 117). Recently, VHFs have developed into global
pandemics and are now considered as threats to biose-
curity. Sub-Saharan Africa provides a rich landscape for
an understanding of the intersections between people,
animals, pathogens, and their broader ecologies. Ebola
outbreaks in this region provide a window to view “disease
transmission between animals and human beings, facili-
tated by the intensified circulation of people, capital, ani-
mals, pathogens, and technologies, (which) are a recurrent
aspect of life on earth, often in highly uneven and unpre-
dictable ways.” ([210], p. 117) However, the reframing of
biological threats in the rhetoric of biosecurity prepared-
ness, with its emphasis on worst-case scenarios, often ob-
scures the multi-causal dimensions, and the sociocultural
and epidemiological consequences of EBOV infection and
EVD pandemics that as often drive the new global public
health agenda.
Considering that the Bracken Bat Cave outside of San
Antonio, Texas holds the largest colony of bats world-
wide, and that bats are the primary vector for EBOV, we
ought to consider developing, in collaboration with Bat
Conservation International, WHO, CDC and Médecins
sans Frontières, a clinical immunotherapy program de-
signed to develop, test and validate anti-EBOV vaccines
for wildlife in general, and specifically targeted to bats.
Given the biodiversity of these volant mammals, their
distribution, patterns of migration and abundance, in-
novative approaches are necessary to control EBOV na-
tionwide and internationally, including oral vaccination
programs similar perhaps to those developed to control
rabid bats and land mammal wildlife in developing
countries [211,212].
However, the significant challenges of controlling the
dynamic fluctuations of bats populations remain [213].
Recent data describing the determinants of viral richness
in 15 species of African bats fully characterized for virus
infection and bat phylogeny in Central and West Africa
point to the need of more extensive knowledge of the
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lutionary fragmentation of bat species in their geo-
graphical distribution and migration across the African
continent and worldwide [214]. Taken together, these
findings will emerge as critical to understand the zoo-
notic transmission of EBOV, and to inform novel inter-
ventions to prevent, control and cure EVD.
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LTF: Lactoferrin; MBGV: Marburg virus; M-CSF: Macrophage colony-stimulating
factor; MCP-1: Monocyte chemotactic protein 1 (also known as CCL2);
MIP-1α-β: macrophage inflammatory protein-1 α-β (also known as CCL3 &
CCL4); MIF: Macrophage migration inhibitory factor; NDUFA12: NADH
dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 12;
PAI1: Plasminogen activator inhibitor 1; PAMP: Pathogen-associated molecular
patterns; PPE: Personal protective equipment; PSMA1: Proteasome subunit
alpha type-1; R0: Contact or exposure rates; RIGI: Retinoic acid inducible gene-I;
RCHY1: Ring-finger and CHY-zinc finger domain-containing protein 1;
RT-PCR: Reverse transcription polymerase chain reaction; RUVBL2: RuvB-like 2
(E. coli), second human homologue of the bacterial RuvB gene; sGP: soluble
glycoprotein; sICAM1: soluble intracellular adhesion molecule 1;
sVCAM1: soluble vascular cell adhesion molecule 1; ssGP: small soluble
glycoprotein; SECIS: Seleno-cysteine insertion sequences; SLC9A7: Solute carrier
family 9, subfamily A, member 7; SLC38A5: Sodium-coupled neutral amino acid
transporter 5; STAT1: Signal transducers and activators of transcription-1; TBK1/
IKKε: TANK-binding kinase 1/IkappaB kinase epsilon; TF: Tissue factor; TIM-1: T
cell immunoglobulin and mucin domain 1; TNF-α: Tumor necrosis factor-α;
Tregs: Regulatory T cell subpopulation (CD4/8 + CD25 + FoxP3+); vGP1,2: viral
glycoprotein 1,2; VHFs: Viral hemorrhagic fevers; VLP: Virus-like particle; VP: Viral
protein; WHO: World Health Organization.
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